Ectopic Pregnancy and Contraception

According to the FSRH, a previous ectopic pregnancy is not an absolute contraindication to the use of intrauterine methods of contraception. In fact, the overall risk of ectopic pregnancy is reduced with the use of IUC when compared to using no contraception. However, if pregnancy does occur with an intrauterine method in situ, the risk of an ectopic pregnancy occurring is increased. In some studies, half of the pregnancies that occurred were ectopic.

It is important to note that older editions of an Australian primary care textbook list an ectopic pregnancy as a contraindication. However, the latest FSRH advice is the reference on which the RCGP is likely to base their answers. Therefore, healthcare professionals should follow the most up-to-date guidelines when considering contraception options for patients with a history of ectopic pregnancy.

Frequent feeding in a breastfed baby doesn’t necessarily indicate low milk supply in the mother. It is uncommon for a mother to have low milk supply, and if the baby is growing well and producing enough urine, it is a good sign that the milk supply is sufficient. In fact, frequent feeding or cluster feeding is normal in the early weeks and helps to establish a good milk supply. Breastfeeding mothers should be encouraged to seek support from local and national breastfeeding groups and consult with a trained professional to ensure proper infant positioning and latch.

There is no need to refer the baby to a pediatrician at this stage. It is not recommended to supplement breastfeeding with formula, especially in the early weeks, as this can decrease milk supply. It is important to feed the baby on demand to stimulate milk production. If milk is not removed from the breast, milk production will decrease.

While maternal prolactin deficiency is a rare cause of low milk supply, testing for it is not necessary in this scenario. If there are signs of low milk supply, such as a baby failing to thrive or becoming dehydrated, and after addressing positioning and latch issues, maternal prolactin deficiency may be considered. Factors that increase the likelihood of this condition include a history of maternal thyroid disorder, eating disorder, hypoplastic breasts, or breast surgery.

For more information on breastfeeding problems, refer to the NICE clinical knowledge summary.

Breastfeeding Problems and Management

Breastfeeding can come with its own set of challenges, but most of them can be managed with proper care and attention. Some common issues include frequent feeding, nipple pain, blocked ducts, and nipple candidiasis. These problems can be addressed by seeking advice on positioning, breast massage, and using appropriate creams and suspensions.

Mastitis is a more serious condition that affects around 1 in 10 breastfeeding women. It is important to seek treatment if symptoms persist or worsen, including systemic illness, nipple fissures, or infection. The first-line antibiotic is flucloxacillin, and breastfeeding or expressing should continue during treatment. If left untreated, mastitis can lead to a breast abscess, which requires incision and drainage.

Breast engorgement is another common issue that can cause pain and discomfort. It usually occurs in the first few days after birth and can affect both breasts. Hand expression of milk can help relieve the discomfort of engorgement, and complications can be avoided by addressing the issue promptly.

Raynaud’s disease of the nipple is a less common but still significant problem that can cause pain and blanching of the nipple. Treatment options include minimizing exposure to cold, using heat packs, avoiding caffeine and smoking, and considering oral nifedipine.

Concerns about poor infant weight gain can also arise, prompting consideration of the above breastfeeding problems and an expert review of feeding. Monitoring of weight until weight gain is satisfactory is also recommended. With proper management and support, most breastfeeding problems can be overcome, allowing for a successful and rewarding breastfeeding experience.

The Faculty of Sexual and Reproductive Healthcare recommends that an intrauterine contraceptive can be inserted right after the evacuation of the uterine cavity following a surgical abortion, provided that it is the woman’s preferred method of contraception.

Termination of Pregnancy in the UK

The UK’s current abortion law is based on the 1967 Abortion Act, which was amended in 1990 to reduce the upper limit for termination from 28 weeks to 24 weeks gestation. To perform an abortion, two registered medical practitioners must sign a legal document, although in emergencies, only one is needed. The procedure must be carried out by a registered medical practitioner in an NHS hospital or licensed premise. The method used to terminate pregnancy depends on the gestation period. For pregnancies less than nine weeks, mifepristone followed by prostaglandins is used, while surgical dilation and suction of uterine contents are used for pregnancies less than 13 weeks. For pregnancies more than 15 weeks, surgical dilation and evacuation of uterine contents or late medical abortion is used. The 1967 Abortion Act outlines the conditions under which a person shall not be guilty of an offense under the law relating to abortion. These limits do not apply in cases where it is necessary to save the life of the woman, there is evidence of extreme fetal abnormality, or there is a risk of serious physical or mental injury to the woman.

Immediate insulin (with or without metformin) should be initiated if the fasting glucose level is equal to or greater than 7 mmol/L at the time of gestational diabetes diagnosis. Glibenclamide may be considered for women who cannot tolerate metformin or do not achieve glucose targets with metformin but decline insulin therapy. If the fasting plasma glucose level is less than 7 mmol/L, lifestyle interventions such as a low glycemic index diet and exercise should be attempted first. If glucose targets are not achieved within 1-2 weeks of lifestyle measures, metformin may be initiated.

Gestational diabetes is a common medical disorder that affects around 4% of pregnancies. It can develop during pregnancy or be a pre-existing condition. According to NICE, 87.5% of cases are gestational diabetes, 7.5% are type 1 diabetes, and 5% are type 2 diabetes. Risk factors for gestational diabetes include a BMI of > 30 kg/m², previous gestational diabetes, a family history of diabetes, and family origin with a high prevalence of diabetes. Screening for gestational diabetes involves an oral glucose tolerance test (OGTT), which should be performed as soon as possible after booking and at 24-28 weeks if the first test is normal.

To diagnose gestational diabetes, NICE recommends using the following thresholds: fasting glucose is >= 5.6 mmol/L or 2-hour glucose is >= 7.8 mmol/L. Newly diagnosed women should be seen in a joint diabetes and antenatal clinic within a week and taught about self-monitoring of blood glucose. Advice about diet and exercise should be given, and if glucose targets are not met within 1-2 weeks of altering diet/exercise, metformin should be started. If glucose targets are still not met, insulin should be added to the treatment plan.

For women with pre-existing diabetes, weight loss is recommended for those with a BMI of > 27 kg/m^2. Oral hypoglycaemic agents, apart from metformin, should be stopped, and insulin should be commenced. Folic acid 5 mg/day should be taken from preconception to 12 weeks gestation, and a detailed anomaly scan at 20 weeks, including four-chamber view of the heart and outflow tracts, should be performed. Tight glycaemic control reduces complication rates, and retinopathy should be treated as it can worsen during pregnancy.

Targets for self-monitoring of pregnant women with diabetes include a fasting glucose level of 5.3 mmol/l and a 1-hour or 2-hour glucose level after meals of 7.8 mmol/l or 6.4 mmol/l, respectively. It is important to manage gestational diabetes and pre-existing diabetes during pregnancy to reduce the risk of complications for both the mother and baby.

For women who have had gestational diabetes, it is recommended to offer a fasting plasma glucose test at 6 weeks after giving birth to rule out diabetes. This is in line with NICE guidelines, which suggest testing between 6-13 weeks postpartum. Testing at 10 days or 2 weeks is not sufficient to accurately assess the risk of developing type 2 diabetes. After 13 weeks, HbA1c testing can be used instead of fasting plasma glucose, but testing at 20 weeks or later is not recommended.

Gestational diabetes is a common medical disorder that affects around 4% of pregnancies. It can develop during pregnancy or be a pre-existing condition. According to NICE, 87.5% of cases are gestational diabetes, 7.5% are type 1 diabetes, and 5% are type 2 diabetes. Risk factors for gestational diabetes include a BMI of > 30 kg/m², previous gestational diabetes, a family history of diabetes, and family origin with a high prevalence of diabetes. Screening for gestational diabetes involves an oral glucose tolerance test (OGTT), which should be performed as soon as possible after booking and at 24-28 weeks if the first test is normal.

To diagnose gestational diabetes, NICE recommends using the following thresholds: fasting glucose is >= 5.6 mmol/L or 2-hour glucose is >= 7.8 mmol/L. Newly diagnosed women should be seen in a joint diabetes and antenatal clinic within a week and taught about self-monitoring of blood glucose. Advice about diet and exercise should be given, and if glucose targets are not met within 1-2 weeks of altering diet/exercise, metformin should be started. If glucose targets are still not met, insulin should be added to the treatment plan.

For women with pre-existing diabetes, weight loss is recommended for those with a BMI of > 27 kg/m^2. Oral hypoglycaemic agents, apart from metformin, should be stopped, and insulin should be commenced. Folic acid 5 mg/day should be taken from preconception to 12 weeks gestation, and a detailed anomaly scan at 20 weeks, including four-chamber view of the heart and outflow tracts, should be performed. Tight glycaemic control reduces complication rates, and retinopathy should be treated as it can worsen during pregnancy.

Targets for self-monitoring of pregnant women with diabetes include a fasting glucose level of 5.3 mmol/l and a 1-hour or 2-hour glucose level after meals of 7.8 mmol/l or 6.4 mmol/l, respectively. It is important to manage gestational diabetes and pre-existing diabetes during pregnancy to reduce the risk of complications for both the mother and baby.

Missed Birth Control Pills

When a woman misses three or more birth control pills in the third week of her cycle, she should complete the third week but skip the pill-free period and start a new pack immediately. This advice is according to the Faculty of Sexual and Reproductive Healthcare (FSRH). It is also recommended to use barrier contraception for seven days. On the other hand, if only one pill is missed, the woman can maintain the pill-free week. It is not usually necessary to extend the pill-free period beyond seven days. However, emergency contraception may be necessary depending on when the pills were missed. It is important to review the latest FSRH guidance before taking any exams.

Preterm labour is a well-known complication for mothers with diabetes during pregnancy.

Complications of Diabetes during Pregnancy

Diabetes during pregnancy can lead to various complications for both the mother and the baby. Maternal complications may include polyhydramnios, which occurs in 25% of cases and may be due to fetal polyuria. Preterm labor is also a common complication, affecting 15% of cases and often associated with polyhydramnios.

Neonatal complications may include macrosomia, although diabetes can also cause small for gestational age babies. Hypoglycemia is another common complication, which occurs due to beta cell hyperplasia. Respiratory distress syndrome may also occur, as surfactant production is delayed. Polycythemia can lead to neonatal jaundice, and malformation rates increase 3-4 fold, including sacral agenesis, CNS and CVS malformations, and hypertrophic cardiomyopathy. Stillbirth, hypomagnesemia, hypocalcemia, and shoulder dystocia (which may cause Erb’s palsy) are also possible complications.

Gestational diabetes is a common medical disorder that affects around 4% of pregnancies. It can develop during pregnancy or be a pre-existing condition. According to NICE, 87.5% of cases are gestational diabetes, 7.5% are type 1 diabetes, and 5% are type 2 diabetes. Risk factors for gestational diabetes include a BMI of > 30 kg/m², previous gestational diabetes, a family history of diabetes, and family origin with a high prevalence of diabetes. Screening for gestational diabetes involves an oral glucose tolerance test (OGTT), which should be performed as soon as possible after booking and at 24-28 weeks if the first test is normal.

To diagnose gestational diabetes, NICE recommends using the following thresholds: fasting glucose is >= 5.6 mmol/L or 2-hour glucose is >= 7.8 mmol/L. Newly diagnosed women should be seen in a joint diabetes and antenatal clinic within a week and taught about self-monitoring of blood glucose. Advice about diet and exercise should be given, and if glucose targets are not met within 1-2 weeks of altering diet/exercise, metformin should be started. If glucose targets are still not met, insulin should be added to the treatment plan.

For women with pre-existing diabetes, weight loss is recommended for those with a BMI of > 27 kg/m^2. Oral hypoglycaemic agents, apart from metformin, should be stopped, and insulin should be commenced. Folic acid 5 mg/day should be taken from preconception to 12 weeks gestation, and a detailed anomaly scan at 20 weeks, including four-chamber view of the heart and outflow tracts, should be performed. Tight glycaemic control reduces complication rates, and retinopathy should be treated as it can worsen during pregnancy.

Targets for self-monitoring of pregnant women with diabetes include a fasting glucose level of 5.3 mmol/l and a 1-hour or 2-hour glucose level after meals of 7.8 mmol/l or 6.4 mmol/l, respectively. It is important to manage gestational diabetes and pre-existing diabetes during pregnancy to reduce the risk of complications for both the mother and baby.

The use of the combined oral contraceptive pill could potentially alleviate certain symptoms experienced during perimenopause and help preserve bone mineral density.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

When it comes to treating infertility in PCOS, clomifene is usually the first choice. Metformin can also be used, but only after anti-oestrogens like clomifene have been tried.

Managing Polycystic Ovarian Syndrome

Polycystic ovarian syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. Its management is complex due to the unclear cause of the condition. However, it is known that PCOS is associated with high levels of luteinizing hormone and hyperinsulinemia, and there is some overlap with the metabolic syndrome. General management includes weight reduction if appropriate and the use of combined oral contraceptives (COC) to regulate the menstrual cycle and induce a monthly bleed.

Hirsutism and acne are common symptoms of PCOS, and a COC pill may be used to manage them. Third-generation COCs with fewer androgenic effects or co-cyprindiol with an anti-androgen action are possible options. If these do not work, topical eflornithine may be tried, or spironolactone, flutamide, and finasteride may be used under specialist supervision.

Infertility is another issue that women with PCOS may face. Weight reduction is recommended if appropriate, and the management of infertility should be supervised by a specialist. There is an ongoing debate about whether metformin, clomifene, or a combination should be used to stimulate ovulation. A 2007 trial published in the New England Journal of Medicine suggested that clomifene was the most effective treatment. However, there is a potential risk of multiple pregnancies with anti-oestrogen therapies such as clomifene. The RCOG published an opinion paper in 2008 and concluded that on current evidence, metformin is not a first-line treatment of choice in the management of PCOS. Metformin is also used, either combined with clomifene or alone, particularly in patients who are obese. Gonadotrophins may also be used.

Statin therapy should not be used during pregnancy due to potential risks. However, paracetamol is considered safe for use during pregnancy. Lamotrigine is preferred over other anti-epileptics due to a lower risk of neurodevelopmental effects on the foetus, but all pregnant women on anti-epileptics should take 5mg folic acid before conception and during the first trimester. Metformin and insulin are commonly used to treat diabetes during pregnancy. It is important to note that all statins should be avoided during pregnancy as they have been associated with congenital anomalies.

Statins are drugs that inhibit the action of HMG-CoA reductase, which is the enzyme responsible for cholesterol synthesis in the liver. However, they can cause adverse effects such as myopathy, liver impairment, and an increased risk of intracerebral hemorrhage in patients with a history of stroke. Statins should not be taken during pregnancy or in combination with macrolides. NICE recommends statins for patients with established cardiovascular disease, a 10-year cardiovascular risk of 10% or higher, type 2 diabetes mellitus, or type 1 diabetes mellitus with certain criteria. It is recommended to take statins at night, especially simvastatin, which has a shorter half-life than other statins. NICE recommends atorvastatin 20 mg for primary prevention and atorvastatin 80 mg for secondary prevention.

Patients on insulin are not always required to inform the DVLA, except for those on temporary treatment for less than three months or those with gestational diabetes who are taking insulin for less than three months after delivery. If a patient falls under these exceptions, they can continue driving but must follow the guidelines for insulin-taking patients, which include checking their blood glucose two hours before driving and every two hours during the journey. It is incorrect to assume that a patient can continue driving as normal without any stipulations, even if they do not need to inform the DVLA.

DVLA Regulations for Drivers with Diabetes Mellitus

The DVLA has recently changed its regulations for drivers with diabetes who use insulin. Previously, these individuals were not allowed to hold an HGV license. However, as of October 2011, the following standards must be met for all drivers using hypoglycemic inducing drugs, including sulfonylureas: no severe hypoglycemic events in the past 12 months, full hypoglycemic awareness, regular blood glucose monitoring at least twice daily and at times relevant to driving, an understanding of the risks of hypoglycemia, and no other complications of diabetes.

For those on insulin who wish to apply for an HGV license, they must complete a VDIAB1I form. Group 1 drivers on insulin can still drive a car as long as they have hypoglycemic awareness, no more than one episode of hypoglycemia requiring assistance within the past 12 months, and no relevant visual impairment. Drivers on tablets or exenatide do not need to notify the DVLA, but if the tablets may induce hypoglycemia, there must not have been more than one episode requiring assistance within the past 12 months. Those who are diet-controlled alone do not need to inform the DVLA.

To demonstrate adequate control, the Honorary Medical Advisory Panel on Diabetes Mellitus recommends that applicants use blood glucose meters with a memory function to measure and record blood glucose levels for at least three months prior to submitting their application. These regulations aim to ensure the safety of all drivers on the road.

The first-line management for nausea and vomiting in pregnancy/hyperemesis gravidarum is antihistamines, specifically oral cyclizine. Second-line options include ondansetron and domperidone. Hospital admission may be necessary if the patient cannot tolerate oral antiemetics or fluids, symptoms are not controlled with primary care management, or hyperemesis gravidarum is suspected. There is no indication for oral omeprazole in this case as the patient has not reported any dyspeptic symptoms.

Hyperemesis gravidarum is a severe form of nausea and vomiting that affects around 1% of pregnancies. It is usually experienced between 8 and 12 weeks of pregnancy but can persist up to 20 weeks. The condition is thought to be related to raised beta hCG levels and is more common in women who are obese, nulliparous, or have multiple pregnancies, trophoblastic disease, or hyperthyroidism. Smoking is associated with a decreased incidence of hyperemesis.

The Royal College of Obstetricians and Gynaecologists recommend that a woman must have a 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance before a diagnosis of hyperemesis gravidarum can be made. Validated scoring systems such as the Pregnancy-Unique Quantification of Emesis (PUQE) score can be used to classify the severity of NVP.

Management of hyperemesis gravidarum involves using antihistamines as a first-line treatment, with oral cyclizine or oral promethazine being recommended by Clinical Knowledge Summaries. Oral prochlorperazine is an alternative, while ondansetron and metoclopramide may be used as second-line treatments. Ginger and P6 (wrist) acupressure can be tried, but there is little evidence of benefit. Admission may be needed for IV hydration.

Complications of hyperemesis gravidarum can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth restriction, preterm birth, and cleft lip/palate (if ondansetron is used during the first trimester). The NICE Clinical Knowledge Summaries recommend considering admission if a woman is unable to keep down liquids or oral antiemetics, has ketonuria and/or weight loss (greater than 5% of body weight), or has a confirmed or suspected comorbidity that may be adversely affected by nausea and vomiting.

Pregnant women with bacterial vaginosis can still use oral metronidazole as it has been found to be safe during pregnancy. Bacterial vaginosis can increase the risk of premature birth and miscarriage. There is no evidence of any harmful effects on the fetus during the first trimester of pregnancy. The guidelines suggest treating symptomatic patients at any stage of pregnancy. While both metronidazole and oral clindamycin can enter breast milk, breastfeeding women are advised to use clindamycin intravaginal gel.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimens. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

To reduce the risk of neural tube defects, women who are trying to conceive and up to 12 weeks into their pregnancy are recommended to take 400 mcg of folic acid. If there are additional risk factors, such as diabetes or a personal or family history of neural tube defects, a higher dose of 5mg is recommended. For bone health, a daily supplement of 10mcg of vitamin D is advised throughout pregnancy and breastfeeding. If a woman chooses to take a multivitamin during pregnancy, she should ensure that it doesn’t contain high doses of vitamin A (retinol) as it can cause birth defects.

Folic Acid: Importance, Deficiency, and Prevention

Folic acid is a vital nutrient that is converted to tetrahydrofolate (THF) in the body. THF plays a crucial role in transferring 1-carbon units to essential substrates involved in DNA and RNA synthesis. Green, leafy vegetables are a good source of folic acid. However, certain medications like phenytoin and methotrexate, pregnancy, and alcohol excess can cause folic acid deficiency. This deficiency can lead to macrocytic, megaloblastic anemia and neural tube defects.

To prevent neural tube defects during pregnancy, all women should take 400mcg of folic acid until the 12th week of pregnancy. Women at higher risk of conceiving a child with a neural tube defect should take 5mg of folic acid from before conception until the 12th week of pregnancy. Women are considered higher risk if either partner has a neural tube defect, they have had a previous pregnancy affected by a neural tube defect, or they have a family history of a neural tube defect. Additionally, women with antiepileptic drugs or coeliac disease, diabetes, or thalassaemia trait, and those who are obese (BMI of 30 kg/m2 or more) are also at higher risk and should take the higher dose of folic acid.

Pregnancy-induced hypertension is typically treated with Labetalol as the initial medication.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, age over 40, high BMI, family history of pre-eclampsia, and multiple pregnancy. To reduce the risk of hypertensive disorders in pregnancy, women with high or moderate risk factors should take aspirin daily. Management involves emergency assessment, admission for severe cases, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

The most appropriate course of action for gestational diabetes is to commence insulin immediately if the fasting glucose level is equal to or greater than 7 mmol/L at the time of diagnosis. While lifestyle changes and co-prescribing metformin should also be discussed, starting insulin is the priority. This is in line with NICE guidelines, which recommend immediate insulin initiation (with or without metformin) and lifestyle advice for glucose levels between 6 and 6.9 mmol/L, especially if there are complications such as macrosomia or hydramnios.

Re-checking the glucose level in two weeks is not appropriate as uncontrolled hyperglycaemia can be dangerous for both the mother and the unborn child.

Starting exenatide is not recommended during pregnancy as there is insufficient data on its safety. Studies in mice have shown adverse effects on fetal and neonatal growth and skeletal development.

Starting metformin alone is not sufficient if the fasting glucose level is greater than 7 mmol/L. However, metformin can be prescribed in combination with insulin.

A trial of lifestyle changes alone is not appropriate if the fasting glucose level is already above 7 mmol/L. If the level is below 7 mmol/L, lifestyle changes can be tried for 1-2 weeks, and if glucose targets are not met, metformin can be offered.

Gestational diabetes is a common medical disorder that affects around 4% of pregnancies. It can develop during pregnancy or be a pre-existing condition. According to NICE, 87.5% of cases are gestational diabetes, 7.5% are type 1 diabetes, and 5% are type 2 diabetes. Risk factors for gestational diabetes include a BMI of > 30 kg/m², previous gestational diabetes, a family history of diabetes, and family origin with a high prevalence of diabetes. Screening for gestational diabetes involves an oral glucose tolerance test (OGTT), which should be performed as soon as possible after booking and at 24-28 weeks if the first test is normal.

To diagnose gestational diabetes, NICE recommends using the following thresholds: fasting glucose is >= 5.6 mmol/L or 2-hour glucose is >= 7.8 mmol/L. Newly diagnosed women should be seen in a joint diabetes and antenatal clinic within a week and taught about self-monitoring of blood glucose. Advice about diet and exercise should be given, and if glucose targets are not met within 1-2 weeks of altering diet/exercise, metformin should be started. If glucose targets are still not met, insulin should be added to the treatment plan.

For women with pre-existing diabetes, weight loss is recommended for those with a BMI of > 27 kg/m^2. Oral hypoglycaemic agents, apart from metformin, should be stopped, and insulin should be commenced. Folic acid 5 mg/day should be taken from preconception to 12 weeks gestation, and a detailed anomaly scan at 20 weeks, including four-chamber view of the heart and outflow tracts, should be performed. Tight glycaemic control reduces complication rates, and retinopathy should be treated as it can worsen during pregnancy.

Targets for self-monitoring of pregnant women with diabetes include a fasting glucose level of 5.3 mmol/l and a 1-hour or 2-hour glucose level after meals of 7.8 mmol/l or 6.4 mmol/l, respectively. It is important to manage gestational diabetes and pre-existing diabetes during pregnancy to reduce the risk of complications for both the mother and baby.

Extra precautions are not necessary when taking antibiotics with the progestogen-only pill.

Counselling for Women Considering the Progestogen-Only Pill

Women who are considering taking the progestogen-only pill (POP) should receive counselling on various aspects of the medication. One of the most common potential adverse effects is irregular vaginal bleeding. It is important to note that the POP should be taken at the same time every day, without a pill-free break, unlike the combined oral contraceptive (COC).

When starting the POP, immediate protection is provided if commenced up to and including day 5 of the cycle. If started later, additional contraceptive methods such as condoms should be used for the first 2 days. If switching from a COC, immediate protection is provided if continued directly from the end of a pill packet.

In case of missed pills, if the delay is less than 3 hours, the pill should be taken as usual. If the delay is more than 3 hours, the missed pill should be taken as soon as possible, and extra precautions such as condoms should be used until pill taking has been re-established for 48 hours.

It is important to note that antibiotics have no effect on the POP, unless the antibiotic alters the P450 enzyme system. Liver enzyme inducers may reduce the effectiveness of the POP. In case of diarrhoea and vomiting, the POP should be continued, but it should be assumed that pills have been missed.

Finally, it is important to discuss sexually transmitted infections (STIs) with healthcare providers when considering the POP. By providing comprehensive counselling, women can make informed decisions about whether the POP is the right contraceptive choice for them.

Due to the increased risk of stillbirth associated with intrahepatic cholestasis of pregnancy, induction of labour is typically recommended at 37-38 weeks gestation. Therefore, a normal labour is not appropriate for this patient. Ursodeoxycholic acid is used to treat the intense pruritus associated with this condition. While a caesarean section may be necessary on an emergency basis, it is not currently indicated at 37-38 weeks. Similarly, a caesarean section at 40 weeks is not currently necessary. Induction of labour at 40 weeks is later than the recommended timeline and may increase the risk of stillbirth.

Understanding Intrahepatic Cholestasis of Pregnancy

Intrahepatic cholestasis of pregnancy, also known as obstetric cholestasis, is a condition that affects approximately 1% of pregnancies in the UK. It is characterized by intense itching, particularly on the palms, soles, and abdomen, and may also result in clinically detectable jaundice in around 20% of patients. Raised bilirubin levels are seen in over 90% of cases.

The management of intrahepatic cholestasis of pregnancy typically involves induction of labor at 37-38 weeks, although this practice may not be evidence-based. Ursodeoxycholic acid is also widely used, although the evidence base for its effectiveness is not clear. Additionally, vitamin K supplementation may be recommended.

It is important to note that the recurrence rate of intrahepatic cholestasis of pregnancy in subsequent pregnancies is high, ranging from 45-90%. Therefore, early diagnosis and management of this condition is crucial for the health and well-being of both the mother and the baby.

Meera’s condition has progressed to pre-eclampsia, indicated by her blood pressure exceeding 140/90 mmHg and the presence of proteinuria at a level of 1+ or higher. As per NICE guidelines, it is imperative that she is promptly admitted to an obstetric unit for close observation and potential intervention.

Hypertension during pregnancy is a common condition that can be managed effectively with proper care. In normal pregnancy, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, if a pregnant woman develops hypertension, it is usually defined as a systolic blood pressure of over 140 mmHg or a diastolic blood pressure of over 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from booking readings can also indicate hypertension.

After confirming hypertension, the patient should be categorized into one of three groups: pre-existing hypertension, pregnancy-induced hypertension (PIH), or pre-eclampsia. PIH, also known as gestational hypertension, occurs in 3-5% of pregnancies and is more common in older women. If a pregnant woman takes an ACE inhibitor or angiotensin II receptor blocker for pre-existing hypertension, it should be stopped immediately, and alternative antihypertensives should be started while awaiting specialist review.

Pregnancy-induced hypertension in association with proteinuria, which occurs in around 5% of pregnancies, may also cause oedema. The 2010 NICE guidelines recommend oral labetalol as the first-line treatment for hypertension during pregnancy. Oral nifedipine and hydralazine may also be used, depending on the patient’s medical history. It is important to manage hypertension during pregnancy effectively to reduce the risk of complications and ensure the health of both the mother and the baby.

Anorexia Nervosa and its Associated Hormonal Changes

Anorexia nervosa is a serious eating disorder that affects many individuals. It is characterized by a distorted body image and an intense fear of gaining weight. Patients with anorexia often experience hormonal changes that can have significant effects on their health.

One of the most common hormonal changes associated with anorexia is functional hypogonadotrophic hypogonadism. This condition is characterized by low levels of follicle-stimulating hormone (FSH) and luteinising hormone (LH). Despite this, plasma testosterone levels are typically normal in females with anorexia.

Cortisol levels may also be affected in patients with anorexia. While they may be within the normal range, they may fail to suppress with dexamethasone. Additionally, basal levels of T3 may be depressed, while thyroxine (T4) and TSH levels may be normal. Finally, ferritin levels are often low in a state of malnutrition.

Overall, anorexia nervosa can have significant effects on a patient’s hormonal balance. It is important for healthcare providers to be aware of these changes and to monitor patients accordingly.

Managing Epilepsy in Pregnancy

During pregnancy, it is important to manage epilepsy carefully to ensure the safety of both the patient and fetus. Uncontrolled seizures pose a greater risk than any potential teratogenic effect of the therapy. However, total plasma concentrations of anticonvulsants may fall during pregnancy, so the dose may need to be increased. It is important to explain the potential teratogenic effects of carbamazepine, particularly neural tube defects, and provide the patient with folate supplements to reduce this risk. Screening with alpha fetoprotein (AFP) and second trimester ultrasound are also required. Prior to delivery, the mother should receive vitamin K. Switching therapies is not recommended as it could precipitate seizures in an otherwise stable patient. It is important to note that both phenytoin and valproate are also associated with teratogenic effects.

A lower occurrence of hyperemesis gravidarum is linked to smoking.

Hyperemesis gravidarum is a severe form of nausea and vomiting that affects around 1% of pregnancies. It is usually experienced between 8 and 12 weeks of pregnancy but can persist up to 20 weeks. The condition is thought to be related to raised beta hCG levels and is more common in women who are obese, nulliparous, or have multiple pregnancies, trophoblastic disease, or hyperthyroidism. Smoking is associated with a decreased incidence of hyperemesis.

The Royal College of Obstetricians and Gynaecologists recommend that a woman must have a 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance before a diagnosis of hyperemesis gravidarum can be made. Validated scoring systems such as the Pregnancy-Unique Quantification of Emesis (PUQE) score can be used to classify the severity of NVP.

Management of hyperemesis gravidarum involves using antihistamines as a first-line treatment, with oral cyclizine or oral promethazine being recommended by Clinical Knowledge Summaries. Oral prochlorperazine is an alternative, while ondansetron and metoclopramide may be used as second-line treatments. Ginger and P6 (wrist) acupressure can be tried, but there is little evidence of benefit. Admission may be needed for IV hydration.

Complications of hyperemesis gravidarum can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth restriction, preterm birth, and cleft lip/palate (if ondansetron is used during the first trimester). The NICE Clinical Knowledge Summaries recommend considering admission if a woman is unable to keep down liquids or oral antiemetics, has ketonuria and/or weight loss (greater than 5% of body weight), or has a confirmed or suspected comorbidity that may be adversely affected by nausea and vomiting.

Pros and Cons of the Combined Oral Contraceptive Pill

The combined oral contraceptive pill is a highly effective method of birth control with a failure rate of less than one per 100 woman years. It is a convenient option that doesn’t interfere with sexual activity and its contraceptive effects are reversible upon stopping. Additionally, it can make periods regular, lighter, and less painful, and may reduce the risk of ovarian, endometrial, and colorectal cancer. It may also protect against pelvic inflammatory disease, ovarian cysts, benign breast disease, and acne vulgaris.

However, there are also some disadvantages to consider. One of the main drawbacks is that people may forget to take it, which can reduce its effectiveness. It also offers no protection against sexually transmitted infections, so additional precautions may be necessary. There is an increased risk of venous thromboembolic disease, breast and cervical cancer, stroke, and ischaemic heart disease, especially in smokers. Temporary side effects such as headache, nausea, and breast tenderness may also be experienced.

Despite some reports of weight gain, a Cochrane review did not find a causal relationship between the combined oral contraceptive pill and weight gain. Overall, the combined oral contraceptive pill can be a safe and effective option for birth control, but it is important to weigh the pros and cons and discuss any concerns with a healthcare provider.

The patient is protected for the next 7 days as she had taken the pill for 7 days in a row previously. According to the FSRH guidelines, emergency contraception is not required after taking seven consecutive pills. However, the guidelines suggest using condoms for the next 7 days in this scenario. Please refer to the provided link for more information.

The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their advice for women taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol. If one pill is missed at any time during the cycle, the woman should take the last pill, even if it means taking two pills in one day, and then continue taking pills daily, one each day. No additional contraceptive protection is needed. However, if two or more pills are missed, the woman should take the last pill, leave any earlier missed pills, and then continue taking pills daily, one each day. She should use condoms or abstain from sex until she has taken pills for seven days in a row. If pills are missed in week one, emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week one. If pills are missed in week two, after seven consecutive days of taking the COC, there is no need for emergency contraception. If pills are missed in week three, she should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of seven days on, seven days off.

Understanding Contraception: A Basic Overview

Contraception has come a long way in the past 50 years, with the development of effective methods being one of the most significant advancements in medicine. There are various types of contraception available, including barrier methods, daily methods, and long-acting methods of reversible contraception (LARCs).

Barrier methods, such as condoms, act as a physical barrier and can help protect against sexually transmitted infections (STIs). However, their success rate is relatively low, particularly when used by young people. Daily methods include the combined oral contraceptive pill, which inhibits ovulation but increases the risk of venous thromboembolism and certain types of cancer. The progesterone-only pill thickens cervical mucous, but irregular bleeding is a common side effect.

LARCs include implantable contraceptives, injectable contraceptives, and intrauterine devices (IUDs). The implantable contraceptive and injectable contraceptive both inhibit ovulation and thicken cervical mucous, with the implant lasting up to three years and the injection lasting 12 weeks. The IUD decreases sperm motility and survival, while the intrauterine system (IUS) prevents endometrial proliferation and thickens cervical mucous, with irregular bleeding being a common side effect.

In summary, understanding the different types of contraception available and their methods of action can help individuals make informed decisions about their reproductive health.

For men with infertility, NICE suggests that the first primary care investigations should include semen analysis and chlamydia screening using a first void urine sample. Additionally, a clinical examination should be conducted to check for any indications of hypogonadism, cryptorchidism, or scrotal masses. It is recommended that a semen sample be produced after abstaining for at least 2 days but no more than 7 days. However, NICE doesn’t recommend screening for antisperm antibodies.

Understanding Infertility: Initial Investigations and Key Counselling Points

Infertility is a common issue that affects approximately 1 in 7 couples. However, it is important to note that around 84% of couples who have regular sex will conceive within 1 year, and 92% within 2 years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

To determine the cause of infertility, basic investigations are typically conducted. These include a semen analysis and a serum progesterone test, which is done 7 days prior to the expected next period. The interpretation of the serum progesterone level is as follows: if the level is less than 16 nmol/l, it should be repeated and if it consistently remains low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

In addition to these investigations, there are key counselling points that should be addressed. These include advising the patient to take folic acid, aiming for a BMI between 20-25, and having regular sexual intercourse every 2 to 3 days. Patients should also be advised to quit smoking and limit alcohol consumption.

By understanding the initial investigations and key counselling points for infertility, healthcare professionals can provide their patients with the necessary information and support to help them conceive.

If a woman is diagnosed with gestational diabetes and her fasting glucose level is equal to or greater than 7 mmol/l, immediate insulin (with or without metformin) should be initiated.

In this scenario, the patient’s fasting glucose level is above 7 mmol/L, indicating the need for immediate insulin therapy (with or without metformin). The diagnosis of gestational diabetes is based on a fasting plasma glucose level of > 5.6 mmol/L or a 2-hour plasma glucose level of >/= 7.8 mmol/L.

While dietary advice is an essential aspect of diabetes management, it is not sufficient in this case due to the elevated fasting glucose level.

Gliclazide is not a suitable option for gestational diabetes treatment because sulfonylureas are not recommended during pregnancy due to the risk of neonatal hypoglycemia.

Metformin may be used in the management of gestational diabetes, but in cases where the fasting glucose level is equal to or greater than 7 mmol/L, insulin is the preferred treatment option. Insulin and metformin can be used together to manage gestational diabetes.

Since both the fasting glucose and 2-hour glucose levels are elevated, there is no need to repeat the test as the diagnosis of gestational diabetes is conclusive.

Gestational diabetes is a common medical disorder that affects around 4% of pregnancies. It can develop during pregnancy or be a pre-existing condition. According to NICE, 87.5% of cases are gestational diabetes, 7.5% are type 1 diabetes, and 5% are type 2 diabetes. Risk factors for gestational diabetes include a BMI of > 30 kg/m², previous gestational diabetes, a family history of diabetes, and family origin with a high prevalence of diabetes. Screening for gestational diabetes involves an oral glucose tolerance test (OGTT), which should be performed as soon as possible after booking and at 24-28 weeks if the first test is normal.

To diagnose gestational diabetes, NICE recommends using the following thresholds: fasting glucose is >= 5.6 mmol/L or 2-hour glucose is >= 7.8 mmol/L. Newly diagnosed women should be seen in a joint diabetes and antenatal clinic within a week and taught about self-monitoring of blood glucose. Advice about diet and exercise should be given, and if glucose targets are not met within 1-2 weeks of altering diet/exercise, metformin should be started. If glucose targets are still not met, insulin should be added to the treatment plan.

For women with pre-existing diabetes, weight loss is recommended for those with a BMI of > 27 kg/m^2. Oral hypoglycaemic agents, apart from metformin, should be stopped, and insulin should be commenced. Folic acid 5 mg/day should be taken from preconception to 12 weeks gestation, and a detailed anomaly scan at 20 weeks, including four-chamber view of the heart and outflow tracts, should be performed. Tight glycaemic control reduces complication rates, and retinopathy should be treated as it can worsen during pregnancy.

Targets for self-monitoring of pregnant women with diabetes include a fasting glucose level of 5.3 mmol/l and a 1-hour or 2-hour glucose level after meals of 7.8 mmol/l or 6.4 mmol/l, respectively. It is important to manage gestational diabetes and pre-existing diabetes during pregnancy to reduce the risk of complications for both the mother and baby.

Contraceptive Methods and Timing

The timing of contraceptive methods is crucial to their effectiveness. The copper-bearing intrauterine device can be used at any time during the menstrual cycle, as long as pregnancy has been reasonably excluded. It doesn’t require any additional contraception. However, if a woman starts taking the combined oral contraceptive pill on day six or later of her menstrual cycle, she needs to use additional contraception or avoid sexual intercourse for seven days. The same applies to the Mirena coil if it is inserted from day eight onwards of the menstrual cycle. The progesterone-only pill and implant also require additional contraception or avoidance of sexual intercourse if started from day six onwards of the menstrual cycle. It is important to understand the timing requirements of each contraceptive method to ensure their effectiveness in preventing pregnancy.

Obstetric cholestasis is the primary cause of itch during pregnancy that is not accompanied by a rash. To diagnose obstetric cholestasis, doctors should look for symptoms such as itchiness that begins in the third trimester, starts on the palms and soles before spreading upwards, worsens at night, and causes severe scratching that leads to excoriation marks. Additionally, patients may report anorexia, malaise, and abdominal pain, which are also associated with obstetric cholestasis.

If a woman displays any of these symptoms, it is recommended that she be admitted to the hospital or referred to an obstetrician on the same day. In secondary care, liver function tests are conducted to confirm the diagnosis, and treatment may include ursodeoxycholic acid and sedating antihistamines.

Jaundice During Pregnancy

During pregnancy, jaundice can occur due to various reasons. One of the most common liver diseases during pregnancy is intrahepatic cholestasis of pregnancy, which affects around 1% of pregnancies and is usually seen in the third trimester. Symptoms include itching, especially in the palms and soles, and raised bilirubin levels. Ursodeoxycholic acid is used for symptomatic relief, and women are typically induced at 37 weeks. However, this condition can increase the risk of stillbirth.

Acute fatty liver of pregnancy is a rare complication that can occur in the third trimester or immediately after delivery. Symptoms include abdominal pain, nausea, vomiting, headache, jaundice, and hypoglycemia. ALT levels are typically elevated. Supportive care is the initial management, and delivery is the definitive management once the patient is stabilized.

Gilbert’s and Dubin-Johnson syndrome may also be exacerbated during pregnancy. Additionally, HELLP syndrome, which stands for Haemolysis, Elevated Liver enzymes, Low Platelets, can also cause jaundice during pregnancy. It is important to monitor liver function tests and seek medical attention if any symptoms of jaundice occur during pregnancy.

AEDs and their effect on oral contraceptive pill efficacy

The metabolism of oestrogen and progestogen is increased by anti-epileptic drugs (AEDs) that induce cytochrome P450. These drugs can be strong inducers, such as carbamazepine, or weaker inducers, such as topiramate. Phenytoin is a strong enzyme inducer. It should be noted that women using lamotrigine should be advised that seizure frequency may increase when initiating the oral contraceptive pill. Additionally, lamotrigine side effects may increase in the pill-free interval or when discontinuing the oral contraceptive pill. Therefore, it is important to consider the potential effects of AEDs on the efficacy of the oral contraceptive pill.

Pre-eclampsia is characterized by a new-onset blood pressure of 140/90 mmHg or higher after 20 weeks of pregnancy, along with either proteinuria or organ dysfunction. In this case, the patient has both high blood pressure and proteinuria, indicating a need for immediate evaluation by the obstetric team in secondary care. Hospitalization and Antihypertensive treatment may be necessary, and delivery may need to be expedited to resolve the condition and prevent complications such as eclamptic fits, coagulation problems, and liver dysfunction.

Given the potential for rapid deterioration, it is not appropriate for the patient to wait for a routine review with her midwife. While labetalol is commonly used to control blood pressure in women with pregnancy-induced hypertension or pre-eclampsia, it should only be initiated and managed under the direction of a specialist. Bisoprolol is not typically used in the treatment of pre-eclampsia.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, age over 40, high BMI, family history of pre-eclampsia, and multiple pregnancy. To reduce the risk of hypertensive disorders in pregnancy, women with high or moderate risk factors should take aspirin daily. Management involves emergency assessment, admission for severe cases, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

The recommended initial treatment for migraines during pregnancy is paracetamol, which is likely to be effective for this patient experiencing a pulsating headache on one side. Aspirin and ibuprofen should be avoided in the third trimester due to the risk of fetal ductal arteriosus closure. Sumatriptan is not considered first-line and should only be used if the potential benefits outweigh the risks, according to the manufacturer’s advice.

Managing Migraine in Relation to Hormonal Factors

Migraine is a common neurological condition that affects many people, particularly women. Hormonal factors such as pregnancy, contraception, and menstruation can have an impact on the management of migraine. In 2008, the Scottish Intercollegiate Guidelines Network (SIGN) produced guidelines on the management of migraine, which provide useful information on how to manage migraine in relation to these hormonal factors.

When it comes to migraine during pregnancy, paracetamol is the first-line treatment, while NSAIDs can be used as a second-line treatment in the first and second trimester. However, aspirin and opioids such as codeine should be avoided during pregnancy. If a patient has migraine with aura, the combined oral contraceptive (COC) pill is absolutely contraindicated due to an increased risk of stroke. Women who experience migraines around the time of menstruation can be treated with mefenamic acid or a combination of aspirin, paracetamol, and caffeine. Triptans are also recommended in the acute situation. Hormone replacement therapy (HRT) is safe to prescribe for patients with a history of migraine, but it may make migraines worse.

In summary, managing migraine in relation to hormonal factors requires careful consideration and appropriate treatment. The SIGN guidelines provide valuable information on how to manage migraine in these situations, and healthcare professionals should be aware of these guidelines to ensure that patients receive the best possible care.

Levonorgestrel dosage should be increased for individuals with a BMI greater than 26 or a weight exceeding 70 kg.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, and should be taken as soon as possible after unprotected sexual intercourse (UPSI) for maximum efficacy. The single dose of levonorgestrel is 1.5mg, but should be doubled for those with a BMI over 26 or weight over 70kg. It is safe and well-tolerated, but may cause vomiting in around 1% of women. Ulipristal, on the other hand, is a selective progesterone receptor modulator that inhibits ovulation. It should be taken within 120 hours after intercourse, and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which may inhibit fertilization or implantation. It must be inserted within 5 days of UPSI, or up to 5 days after the likely ovulation date. Prophylactic antibiotics may be given if the patient is at high-risk of sexually transmitted infection. The IUD is 99% effective regardless of where it is used in the cycle, and may be left in-situ for long-term contraception.

Pathogens and Pregnancy: What You Need to Know

Although various pathogens can colonize and infect the vagina during pregnancy, only syphilis is routinely tested for. Adequate treatment of syphilis before 18 weeks of pregnancy can prevent infection of the fetus, while treatment after 18 weeks can cure an infected fetus. Failure to treat syphilis can result in congenital syphilis, which can have long-term consequences.

herpesvirus is not routinely screened for during pregnancy, but if a woman contracts genital herpes for the first time during the first trimester, there is a small risk of miscarriage. If first infection occurs later in the pregnancy, a caesarean section may be offered to prevent the baby from coming into contact with active sores. The risk of passing on a newly caught infection to the baby during vaginal birth is about 4 in 10, but neonatal herpes is very rare in the UK, affecting only 1-2 in every 100,000 babies born.

Strep B is not routinely tested for during pregnancy, but about one in five pregnant women in the UK carry group B Streptococci bacteria. While most pregnant women who carry these bacteria have healthy babies, there is a small risk that infection can pass to the baby during childbirth. Group B Strep infection in newborn babies can cause serious complications that can be life-threatening, and even with the best medical care, one in 10 babies diagnosed with early-onset infection will die.

HPV and gonorrhea are not routinely tested for during pregnancy. It is important for pregnant women to discuss any concerns about sexually transmitted infections with their healthcare provider to ensure the best possible outcomes for themselves and their babies.

Using combined hormonal contraceptive pills (CHC) can be beneficial for women in their 40s and beyond. It can reduce menstrual bleeding and pain, as well as alleviate menopausal symptoms. CHC with levonorgestrel or norethisterone are recommended as they have a lower risk of venous thromboembolism compared to other progestogens. However, it is important to note that there are risks associated with CHC use, and women should be informed of these before deciding to use it. The Faculty of Sexual and Reproductive Health advises that CHC can be used until age 50, but after that, women should switch to non-hormonal methods as the risks of CHC generally outweigh the benefits. Women who wish to continue using CHC after age 50 should be assessed on an individual basis. Extended or continuous CHC regimens can also be used for contraception and to manage menstrual or menopausal symptoms. Additionally, CHC is associated with a reduced risk of ovarian and endometrial cancer that can last for several decades after stopping use. Finally, CHC may help maintain bone mineral density during the perimenopause compared to not using hormones.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

According to NICE guidelines, women who are at high risk of VTE and are seeking HRT should be referred to a haematologist before starting any treatment, even if it is transdermal. While the risk of VTE associated with HRT is higher for oral preparations than transdermal ones, the risk for transdermal HRT at standard therapeutic doses is not greater than the baseline risk. However, for women with a significant baseline risk, such as those with a strong family history of VTE or a hereditary thrombophilia, referral to a haematologist for assessment is recommended before considering HRT. Therefore, all options that suggest prescribing HRT are incorrect, with oral prescription being the most problematic. It is not enough to advise this woman to manage her symptoms conservatively, as there is clear guidance to refer her to a specialist for additional help.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progestogen, to alleviate menopausal symptoms. However, this treatment can have side-effects such as nausea, breast tenderness, fluid retention, and weight gain.

Moreover, there are potential complications associated with HRT. One of the most significant risks is an increased likelihood of breast cancer, particularly when a progestogen is added. The Women’s Health Initiative (WHI) study found that the relative risk of developing breast cancer was 1.26 after five years of HRT use. The risk of breast cancer is related to the duration of HRT use, and it begins to decline when the treatment is stopped. Additionally, HRT use can increase the risk of endometrial cancer, which can be reduced but not eliminated by adding a progestogen.

Another potential complication of HRT is an increased risk of venous thromboembolism (VTE), particularly when a progestogen is added. However, transdermal HRT doesn’t appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any HRT treatment, even transdermal. Finally, HRT use can increase the risk of stroke and ischaemic heart disease if taken more than ten years after menopause.

In conclusion, while HRT can be an effective treatment for menopausal symptoms, it is essential to be aware of the potential adverse effects and complications associated with this treatment. Women should discuss the risks and benefits of HRT with their healthcare provider before starting any treatment.

Pregnant women should not take warfarin and are typically prescribed low-molecular weight heparin instead throughout their pregnancy.

Prescribing Considerations for Pregnant Patients

When it comes to prescribing medication for pregnant patients, it is important to exercise caution as very few drugs are known to be completely safe during pregnancy. Some countries have developed a grading system to help guide healthcare professionals in their decision-making process. It is important to note that the following drugs are known to be harmful and should be avoided: tetracyclines, aminoglycosides, sulphonamides and trimethoprim, quinolones, ACE inhibitors, angiotensin II receptor antagonists, statins, warfarin, sulfonylureas, retinoids (including topical), and cytotoxic agents.

In addition, the majority of antiepileptics, including valproate, carbamazepine, and phenytoin, are potentially harmful. However, the decision to stop such treatments can be difficult as uncontrolled epilepsy poses its own risks. It is important for healthcare professionals to carefully weigh the potential risks and benefits of any medication before prescribing it to a pregnant patient.

An appropriate substitute would be mefenamic acid in oral form.

Managing Migraine in Relation to Hormonal Factors

Migraine is a common neurological condition that affects many people, particularly women. Hormonal factors such as pregnancy, contraception, and menstruation can have an impact on the management of migraine. In 2008, the Scottish Intercollegiate Guidelines Network (SIGN) produced guidelines on the management of migraine, which provide useful information on how to manage migraine in relation to these hormonal factors.

When it comes to migraine during pregnancy, paracetamol is the first-line treatment, while NSAIDs can be used as a second-line treatment in the first and second trimester. However, aspirin and opioids such as codeine should be avoided during pregnancy. If a patient has migraine with aura, the combined oral contraceptive (COC) pill is absolutely contraindicated due to an increased risk of stroke. Women who experience migraines around the time of menstruation can be treated with mefenamic acid or a combination of aspirin, paracetamol, and caffeine. Triptans are also recommended in the acute situation. Hormone replacement therapy (HRT) is safe to prescribe for patients with a history of migraine, but it may make migraines worse.

In summary, managing migraine in relation to hormonal factors requires careful consideration and appropriate treatment. The SIGN guidelines provide valuable information on how to manage migraine in these situations, and healthcare professionals should be aware of these guidelines to ensure that patients receive the best possible care.

Sterilisation as a Permanent Contraceptive Method

Sterilisation is a permanent contraceptive method with an overall failure rate of approximately 1 per 200. However, the individual failure rate may be lower depending on the method used. It is important to note that sterilisation should be considered permanent, even though reversal is possible. This is because it is an operation performed with the intention of being permanent and reversal cannot be guaranteed.

The proportion of women expressing regret after undergoing sterilisation varies between different studies and different countries but tends to range from 3% to 10% in the United Kingdom. Sterilisation is usually done laparoscopically, although methods involving a vaginal approach are possible.

It is crucial to counsel patients about the effectiveness of other contraceptive methods that are as effective as sterilisation. Patients may not be aware of this, and it may alter their decision. For some, a long-acting form of contraception such as the intrauterine system (Mirena) may be more acceptable and preferable. Therefore, it is essential to discuss all available options with patients to help them make an informed decision about their contraceptive choices.

The patient should be informed that their future fertility is not impacted by the abortion and there is no association with placenta praevia, ectopic pregnancy, stillborn or miscarriage. However, they should also be made aware of the potential complications that may arise from the procedure. These include severe bleeding, uterine perforation (surgical abortion only), and cervical trauma (surgical abortion only). The risks of these complications are lower for early abortions and those performed by experienced clinicians. In the event that one of these complications occurs, further treatment such as blood transfusion, laparoscopy or laparotomy may be required. Additionally, infection may occur after medical or surgical abortion, but this risk can be reduced through prophylactic antibiotic use and bacterial screening for lower genital tract infection.

Termination of Pregnancy in the UK

The UK’s current abortion law is based on the 1967 Abortion Act, which was amended in 1990 to reduce the upper limit for termination from 28 weeks to 24 weeks gestation. To perform an abortion, two registered medical practitioners must sign a legal document, although in emergencies, only one is needed. The procedure must be carried out by a registered medical practitioner in an NHS hospital or licensed premise. The method used to terminate pregnancy depends on the gestation period. For pregnancies less than nine weeks, mifepristone followed by prostaglandins is used, while surgical dilation and suction of uterine contents are used for pregnancies less than 13 weeks. For pregnancies more than 15 weeks, surgical dilation and evacuation of uterine contents or late medical abortion is used. The 1967 Abortion Act outlines the conditions under which a person shall not be guilty of an offense under the law relating to abortion. These limits do not apply in cases where it is necessary to save the life of the woman, there is evidence of extreme fetal abnormality, or there is a risk of serious physical or mental injury to the woman.

Initiation of Combined Hormonal Contraception Postpartum

Combined hormonal contraception can be safely started by eligible women 21 days after giving birth, provided they have no other risk factors for venous thromboembolism and are not breastfeeding. However, women who breastfeed and want to use combined hormonal contraception should wait until six weeks postpartum, regardless of whether they have additional risk factors for VTE. Studies have shown conflicting effects of combined oral contraception on breastfeeding, with some indicating less weight gain in infants of users compared to non-users when started at or before six weeks postpartum. No study has demonstrated an effect on infant weight gain when initiated after six weeks postpartum. It is important for healthcare providers to consider individual patient factors and preferences when discussing contraceptive options postpartum.

Managing Low Libido in Menopausal Women

Lubricants can provide temporary relief for menopausal women experiencing low libido, but they require frequent application and may not address the underlying issue. Measuring testosterone levels is not a reliable method for diagnosing low libido in menopausal women. While testosterone patches can benefit naturally menopausal women, they are currently only licensed for use in women who have had their ovaries removed. However, it is important to note that the postmenopausal ovary does produce testosterone. Tibolone is a medication that has been shown to improve low libido in postmenopausal women. It is important for women experiencing low libido to discuss their symptoms with their healthcare provider to determine the best course of treatment.

Treatment Options for Urinary Incontinence

Bladder training is a highly effective treatment for urge or mixed incontinence. It has fewer adverse effects and lower relapse rates compared to antimuscarinic drugs, which are the next line of treatment. On the other hand, pelvic floor muscle training is recommended as the first line of treatment for stress incontinence symptoms.

Duloxetine is only recommended for stress incontinence and may be offered as a second-line treatment for women who prefer pharmacological treatment over surgery. However, modification of fluid intake is not routinely recommended. It is only recommended if fluid intake is high or low and in cases of urinary incontinence or overactive bladder.

In summary, there are various treatment options available for urinary incontinence, depending on the type and severity of the symptoms. It is important to consult with a healthcare professional to determine the most appropriate treatment plan.

Antiphospholipid Syndrome and Pregnancy: Risks and Management

Antiphospholipid syndrome is a condition that increases the risk of both venous and arterial blood clots, recurrent miscarriage, and low platelet count. It can occur as a primary disorder or as a secondary condition to other illnesses, such as systemic lupus erythematosus. When a woman with antiphospholipid syndrome becomes pregnant, there are several potential complications that may arise, including pre-eclampsia, placental abruption, and preterm delivery.

To manage these risks, low-dose aspirin is typically prescribed as soon as the pregnancy is confirmed through a urine test. Once a fetal heartbeat is detected on ultrasound, low molecular weight heparin is added to the treatment plan. This medication is usually discontinued at 34 weeks gestation. These interventions have been shown to increase the live birth rate by seven-fold. It is important for women with antiphospholipid syndrome to work closely with their healthcare provider to ensure the best possible outcome for both mother and baby.

Extra precautions should be taken during the first 7 days of starting the combined oral contraceptive pill as it doesn’t provide immediate protection when initiated on day 6 of the menstrual cycle. Women over the age of 35 who smoke should not use this form of contraception.

Women who are considering taking the combined oral contraceptive pill (COC) should receive counselling on various aspects. This includes the potential benefits and harms of the COC, such as its high effectiveness rate of over 99% when taken correctly, but also the small risk of blood clots, heart attacks, strokes, and increased risk of breast and cervical cancer. Additionally, advice on taking the pill should be provided, such as starting it within the first 5 days of the cycle to avoid the need for additional contraception, taking it at the same time every day, and considering tailored regimens that eliminate the pill-free interval. It is also important to discuss situations where efficacy may be reduced, such as vomiting or taking liver enzyme-inducing drugs. Finally, counselling should include information on STIs and the use of concurrent antibiotics, which may no longer require extra precautions except for enzyme-inducing antibiotics like rifampicin.

Overall, women should receive comprehensive counselling on the COC to make informed decisions about their reproductive health. This includes discussing the potential benefits and harms, advice on taking the pill, and situations where efficacy may be reduced. By providing this information, women can make informed decisions about their contraceptive options and reduce the risk of unintended pregnancies.

New intrauterine contraceptive devices include the Jaydess® IUS and Kyleena® IUS. The Jaydess® IUS is licensed for 3 years and has a smaller frame, narrower inserter tube, and less levonorgestrel than the Mirena® coil. The Kyleena® IUS has 19.5mg LNG, is smaller than the Mirena®, and is licensed for 5 years. Both result in lower serum levels of LNG, but the rate of amenorrhoea is less with Kyleena® compared to Mirena®.

The license for using Mirena as endometrial protection for women on oestrogen-only HRT is limited to 4 years. Similarly, intrauterine contraceptives are licensed for a duration of 3 years.

New intrauterine contraceptive devices include the Jaydess® IUS and Kyleena® IUS. The Jaydess® IUS is licensed for 3 years and has a smaller frame, narrower inserter tube, and less levonorgestrel than the Mirena® coil. The Kyleena® IUS has 19.5mg LNG, is smaller than the Mirena®, and is licensed for 5 years. Both result in lower serum levels of LNG, but the rate of amenorrhoea is less with Kyleena® compared to Mirena®.

If a person misses two pills between days 8-14 of their cycle while taking the combined oral contraceptive pill (COCP) correctly for the previous seven days, emergency contraception is not necessary. This is the case for a patient who is currently in the second week of taking the pill and has had unprotected sex during this time. However, they should use additional precautions for the next seven days. Emergency contraception would only be necessary if the patient had unprotected sex during the first week of taking the pill or during the pill-free week, or if they had not taken at least seven consecutive pills prior to the episode of unprotected sex. It is important to use additional precautions for seven days, rather than restarting the pill as normal or with only two days of additional precautions. The pill-free interval doesn’t need to be omitted if the patient misses pills only during the second week of taking the pill.

The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their advice for women taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol. If one pill is missed at any time during the cycle, the woman should take the last pill, even if it means taking two pills in one day, and then continue taking pills daily, one each day. No additional contraceptive protection is needed. However, if two or more pills are missed, the woman should take the last pill, leave any earlier missed pills, and then continue taking pills daily, one each day. She should use condoms or abstain from sex until she has taken pills for seven days in a row. If pills are missed in week one, emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week one. If pills are missed in week two, after seven consecutive days of taking the COC, there is no need for emergency contraception. If pills are missed in week three, she should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of seven days on, seven days off.

Couples, including those with fertility issues, have a 15-20% chance of conceiving naturally within a year through regular unprotected sexual intercourse. However, this patient’s PCOS condition, which causes ovulation insufficiency, may prolong the process. Hence, a referral is necessary for assistance, and treatment with clomifene to stimulate ovulation would be suitable.

Managing Polycystic Ovarian Syndrome

Polycystic ovarian syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. Its management is complex due to the unclear cause of the condition. However, it is known that PCOS is associated with high levels of luteinizing hormone and hyperinsulinemia, and there is some overlap with the metabolic syndrome. General management includes weight reduction if appropriate and the use of combined oral contraceptives (COC) to regulate the menstrual cycle and induce a monthly bleed.

Hirsutism and acne are common symptoms of PCOS, and a COC pill may be used to manage them. Third-generation COCs with fewer androgenic effects or co-cyprindiol with an anti-androgen action are possible options. If these do not work, topical eflornithine may be tried, or spironolactone, flutamide, and finasteride may be used under specialist supervision.

Infertility is another issue that women with PCOS may face. Weight reduction is recommended if appropriate, and the management of infertility should be supervised by a specialist. There is an ongoing debate about whether metformin, clomifene, or a combination should be used to stimulate ovulation. A 2007 trial published in the New England Journal of Medicine suggested that clomifene was the most effective treatment. However, there is a potential risk of multiple pregnancies with anti-oestrogen therapies such as clomifene. The RCOG published an opinion paper in 2008 and concluded that on current evidence, metformin is not a first-line treatment of choice in the management of PCOS. Metformin is also used, either combined with clomifene or alone, particularly in patients who are obese. Gonadotrophins may also be used.

Hormone Therapy Contraindicated in Breast Cancer Patient

Hormone therapies are not an option for a woman with a history of breast cancer due to contraindications. This rules out all hormone therapy options. Additionally, fluoxetine, which inhibits the enzyme that converts tamoxifen to its active metabolite, should not be used in this case. This is because it reduces the amount of active drug that is released.

The most appropriate treatment option for low mood in the absence of depression is cognitive behavioral therapy (CBT). While it may not help with menopausal flashes, it is recommended by NICE and is the best choice from the list of options provided.

Overall, it is important to consider a patient’s medical history and any contraindications before prescribing any treatment options. In this case, hormone therapy and fluoxetine are not suitable, and CBT is the recommended course of action.

Having a short inter-pregnancy interval of less than 12 months between childbirth and conceiving again can lead to a higher likelihood of preterm birth, low birthweight, and small for gestational age babies. Women should be informed of this risk, and it is currently recommended by the World Health Organisation to wait at least 24 months after childbirth before getting pregnant again. It is important to note that the risk associated with a short inter-pregnancy interval is still relatively low.

After giving birth, women need to use contraception after 21 days. The Progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first 2 days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the Combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than 6 weeks postpartum. If breastfeeding is between 6 weeks to 6 months postpartum, it is UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk postpartum. After day 21, additional contraception should be used for the first 7 days.

The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after 4 weeks. Meanwhile, the Lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than 6 months postpartum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

The effectiveness of hormonal contraception may be reduced by EllaOne. To ensure proper contraception, individuals using the pill, patch, or ring should wait 5 days after taking Ulipristal before starting or restarting their contraception. During this period, it is recommended to use barrier methods.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, and should be taken as soon as possible after unprotected sexual intercourse (UPSI) for maximum efficacy. The single dose of levonorgestrel is 1.5mg, but should be doubled for those with a BMI over 26 or weight over 70kg. It is safe and well-tolerated, but may cause vomiting in around 1% of women. Ulipristal, on the other hand, is a selective progesterone receptor modulator that inhibits ovulation. It should be taken within 120 hours after intercourse, and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which may inhibit fertilization or implantation. It must be inserted within 5 days of UPSI, or up to 5 days after the likely ovulation date. Prophylactic antibiotics may be given if the patient is at high-risk of sexually transmitted infection. The IUD is 99% effective regardless of where it is used in the cycle, and may be left in-situ for long-term contraception.

Understanding Postpartum Mental Health Problems

Postpartum mental health problems can range from mild ‘baby-blues’ to severe puerperal psychosis. To screen for depression, healthcare professionals may use the Edinburgh Postnatal Depression Scale, which is a 10-item questionnaire that indicates how the mother has felt over the previous week. A score of over 13 indicates a ‘depressive illness of varying severity’, and the questionnaire includes a question about self-harm. The sensitivity and specificity of this screening tool are over 90%.

‘Baby-blues’ are seen in around 60-70% of women and typically occur 3-7 days following birth. This condition is more common in primips, and mothers are characteristically anxious, tearful, and irritable. Postnatal depression affects around 10% of women, with most cases starting within a month and typically peaking at 3 months. The features of postnatal depression are similar to depression seen in other circumstances.

Puerperal psychosis affects approximately 0.2% of women and usually occurs within the first 2-3 weeks following birth. The features of this condition include severe swings in mood (similar to bipolar disorder) and disordered perception (e.g. auditory hallucinations). Reassurance and support are important for all these conditions, but admission to hospital is usually required for puerperal psychosis, ideally in a Mother & Baby Unit. Cognitive behavioural therapy may be beneficial, and certain SSRIs such as sertraline and paroxetine may be used if symptoms are severe. While these medications are secreted in breast milk, they are not thought to be harmful to the infant. However, fluoxetine is best avoided due to its long half-life. There is around a 25-50% risk of recurrence following future pregnancies.

The copper IUD can be used until menopause if inserted at age 40 or over, according to the FSRH. It can remain in place for 1 year after the last menstrual period if the woman is over 50, or 2 years if she is under 50. It should not be left in place indefinitely due to the risk of infection.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

Understanding Vulvovaginitis

Vulvovaginitis is a common condition that can have various causes, including lichen sclerosus, VIN, and other dermatological conditions. However, in young women, an inflammatory vulval dermatitis is often the culprit, triggered by factors such as soaps, frequent washing, perfumes, sanitary towels, douching, or candidiasis.

The initial treatment for this condition typically involves a combination of topical steroid and antifungal preparations. While STI screening and specialist referrals are not usually necessary, it’s important to offer a chaperone during same-sex examinations and consider them mandatory for opposite-sex examinations.

It’s worth noting that lack of estrogen is not typically a cause of vulvovaginitis, and vulval biopsy is not usually indicated based on the information available. By understanding the causes and appropriate treatments for vulvovaginitis, healthcare providers can help their patients manage this common condition effectively.

The patient is experiencing recurrent migraines with classic symptoms such as unilateral and pulsating headache. However, topiramate is not the best option as it can reduce the effectiveness of hormonal contraception, including both the combined oral contraceptive pill and the progestogen-only pill (UKMEC 3 (disadvantages outweigh advantages)). Instead, alternative options such as triptans and NSAIDs can be used as monotherapy or in combination for acute treatment. Propranolol is also a suitable preventative treatment for women who are of childbearing age or those who are on hormonal contraceptives.

Topiramate: Mechanisms of Action and Contraceptive Considerations

Topiramate is a medication primarily used to treat seizures. It can be used alone or in combination with other drugs. The drug has multiple mechanisms of action, including blocking voltage-gated Na+ channels, increasing GABA action, and inhibiting carbonic anhydrase. The latter effect results in a decrease in urinary citrate excretion and the formation of alkaline urine, which favors the creation of calcium phosphate stones.

Topiramate is known to induce the P450 enzyme CYP3A4, which can reduce the effectiveness of hormonal contraception. Therefore, the Faculty of Sexual and Reproductive Health (FSRH) recommends that patients taking topiramate consider alternative forms of contraception. For example, the combined oral contraceptive pill and progestogen-only pill are not recommended, while the implant is generally considered safe.

Topiramate can cause several side effects, including reduced appetite and weight loss, dizziness, paraesthesia, lethargy, and poor concentration. However, the most significant risk associated with topiramate is the potential for fetal malformations. Additionally, rare but important side effects include acute myopia and secondary angle-closure glaucoma. Overall, topiramate is a useful medication for treating seizures, but patients should be aware of its potential side effects and contraceptive considerations.

Interpretation of Patient’s Symptoms

This patient is exhibiting symptoms that suggest hypercalcaemia, which is a clinically significant condition. It is important to note that the free T4 level is at the lower end of the normal range, which is common during pregnancy. Therefore, TSH is a better indicator of thyroid function. Additionally, hyperprolactinaemia and detectable urinary human chorionic gonadotrophin are normal findings during pregnancy. It is also typical for serum alkaline phosphatase levels to increase up to four times the normal range due to increased placental production.

Overall, it is essential to consider the patient’s pregnancy status when interpreting their symptoms and laboratory results.

The Jaydess IUS is licensed for 3 years and has a smaller frame and less levonorgestrel than the Mirena coil. The Mirena coil is licensed for 5 years, while the Kyleena IUS has 19.5mg LNG and is also licensed for 5 years. The copper IUD is licensed for 5 years.

New intrauterine contraceptive devices include the Jaydess® IUS and Kyleena® IUS. The Jaydess® IUS is licensed for 3 years and has a smaller frame, narrower inserter tube, and less levonorgestrel than the Mirena® coil. The Kyleena® IUS has 19.5mg LNG, is smaller than the Mirena®, and is licensed for 5 years. Both result in lower serum levels of LNG, but the rate of amenorrhoea is less with Kyleena® compared to Mirena®.

The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their advice for women taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol. If one pill is missed at any time during the cycle, the woman should take the last pill, even if it means taking two pills in one day, and then continue taking pills daily, one each day. No additional contraceptive protection is needed. However, if two or more pills are missed, the woman should take the last pill, leave any earlier missed pills, and then continue taking pills daily, one each day. She should use condoms or abstain from sex until she has taken pills for seven days in a row. If pills are missed in week one, emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week one. If pills are missed in week two, after seven consecutive days of taking the COC, there is no need for emergency contraception. If pills are missed in week three, she should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of seven days on, seven days off.

The appropriate course of action for a woman exhibiting symptoms of agitation and paranoid delusions after giving birth is to admit her to the hospital for urgent assessment. This is likely a case of postpartum psychosis, which is different from postnatal depression. Prescribing medication to aid in sleep or reassuring the patient that her low mood will improve with time are not appropriate options in this case. Gradual titration of medication would also not manage her acute symptoms and ensure the safety of herself and her baby. Ideally, she should be admitted to a Mother & Baby Unit for proper care.

Understanding Postpartum Mental Health Problems

Postpartum mental health problems can range from mild ‘baby-blues’ to severe puerperal psychosis. To screen for depression, healthcare professionals may use the Edinburgh Postnatal Depression Scale, which is a 10-item questionnaire that indicates how the mother has felt over the previous week. A score of over 13 indicates a ‘depressive illness of varying severity’, and the questionnaire includes a question about self-harm. The sensitivity and specificity of this screening tool are over 90%.

‘Baby-blues’ are seen in around 60-70% of women and typically occur 3-7 days following birth. This condition is more common in primips, and mothers are characteristically anxious, tearful, and irritable. Postnatal depression affects around 10% of women, with most cases starting within a month and typically peaking at 3 months. The features of postnatal depression are similar to depression seen in other circumstances.

Puerperal psychosis affects approximately 0.2% of women and usually occurs within the first 2-3 weeks following birth. The features of this condition include severe swings in mood (similar to bipolar disorder) and disordered perception (e.g. auditory hallucinations). Reassurance and support are important for all these conditions, but admission to hospital is usually required for puerperal psychosis, ideally in a Mother & Baby Unit. Cognitive behavioural therapy may be beneficial, and certain SSRIs such as sertraline and paroxetine may be used if symptoms are severe. While these medications are secreted in breast milk, they are not thought to be harmful to the infant. However, fluoxetine is best avoided due to its long half-life. There is around a 25-50% risk of recurrence following future pregnancies.

Causes of Vaginal Discharge in Women

This woman is experiencing occasional vaginal discharge. There are several potential causes of vaginal discharge, including candidiasis, bacterial vaginosis, and physiological discharge. Candidiasis is typically associated with itch and a thick discharge, while bacterial vaginosis is often intermittent and accompanied by a profuse and smelly discharge. However, given the patient’s age and stable relationship, physiological discharge is the most likely cause.

In this case, it may not be necessary to conduct a speculum exam unless the patient specifically requests it. Initially, the patient can be reassured without further investigation. However, if investigation is deemed necessary, a self-taken lower vaginal swab would be a reasonable option.

It is important to note that normality is a common theme in the MRCGP exam, and understanding the various causes of vaginal discharge is an important aspect of primary care.

When pregnant women are exposed to Chickenpox, it is important to inquire about their prior history of the infection. If they are uncertain or have not had it before, it is recommended to test for varicella antibodies. In cases where they are found to be non-immune, varicella immunoglobulin should be considered. This treatment can be administered at any stage of pregnancy and is effective for up to 10 days following exposure.

Chickenpox Exposure in Pregnancy: Risks and Management

Chickenpox is caused by the varicella-zoster virus and can pose risks to both the mother and fetus during pregnancy. The mother is at a five times greater risk of pneumonitis, while the fetus is at risk of developing fetal varicella syndrome (FVS) if the mother is exposed to Chickenpox before 20 weeks gestation. FVS can result in skin scarring, eye defects, limb hypoplasia, microcephaly, and learning disabilities. There is also a risk of shingles in infancy and severe neonatal varicella if the mother develops a rash between 5 days before and 2 days after birth.

To manage Chickenpox exposure in pregnancy, post-exposure prophylaxis (PEP) may be necessary. If the pregnant woman is not immune to varicella, VZIG or antivirals may be given within 10 days of exposure. Waiting until days 7-14 is recommended to reduce the risk of developing clinical varicella. However, the decision on choice of PEP for women exposed from 20 weeks of pregnancy should take into account patient and health professional preference as well as the ability to offer and provide PEP in a timely manner.

If a pregnant woman develops Chickenpox, specialist advice should be sought. Oral aciclovir may be given if the pregnant woman is ≥ 20 weeks and presents within 24 hours of onset of the rash. However, caution should be exercised if the woman is < 20 weeks. Overall, managing Chickenpox exposure in pregnancy requires careful consideration of the risks and benefits to both the mother and fetus.

If a woman has a suspected or personal history of breast cancer or a confirmed BRCA mutation, the safest form of contraception for her is the copper coil. The UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) provides guidelines for the choice of contraception, grading non-barrier contraceptives on a scale of 1-4 based on a woman’s personal circumstances. Contraceptive methods that fall under category 1 or 2 are generally considered safe for use in primary care. In this case, all forms of contraception except the combined pill (category 3) can be offered, with the copper coil being the safest option as it falls under category 1.

Understanding Contraception: A Basic Overview

Contraception has come a long way in the past 50 years, with the development of effective methods being one of the most significant advancements in medicine. There are various types of contraception available, including barrier methods, daily methods, and long-acting methods of reversible contraception (LARCs).

Barrier methods, such as condoms, act as a physical barrier and can help protect against sexually transmitted infections (STIs). However, their success rate is relatively low, particularly when used by young people. Daily methods include the combined oral contraceptive pill, which inhibits ovulation but increases the risk of venous thromboembolism and certain types of cancer. The progesterone-only pill thickens cervical mucous, but irregular bleeding is a common side effect.

LARCs include implantable contraceptives, injectable contraceptives, and intrauterine devices (IUDs). The implantable contraceptive and injectable contraceptive both inhibit ovulation and thicken cervical mucous, with the implant lasting up to three years and the injection lasting 12 weeks. The IUD decreases sperm motility and survival, while the intrauterine system (IUS) prevents endometrial proliferation and thickens cervical mucous, with irregular bleeding being a common side effect.

In summary, understanding the different types of contraception available and their methods of action can help individuals make informed decisions about their reproductive health.

Typically, cervical screening is postponed until 3 months after giving birth, unless there was a missed screening or previous abnormal results. Smear tests are not conducted while pregnant, and there is no reason to refer for colposcopy based on the patient’s history. It is standard practice to delay smear tests until 3 months after delivery.

Understanding Cervical Cancer Screening in the UK

Cervical cancer screening is a well-established program in the UK that aims to detect Premalignant changes in the cervix. This program is estimated to prevent 1,000-4,000 deaths per year. However, it should be noted that cervical adenocarcinomas, which account for around 15% of cases, are frequently undetected by screening.

The screening program has evolved significantly in recent years. Initially, smears were examined for signs of dyskaryosis, which may indicate cervical intraepithelial neoplasia. However, the introduction of HPV testing allowed for further risk stratification. Patients with mild dyskaryosis who were HPV negative could be treated as having normal results. The NHS has now moved to an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

All women between the ages of 25-64 years are offered a smear test. Women aged 25-49 years are screened every three years, while those aged 50-64 years are screened every five years. Cervical screening cannot be offered to women over 64, unlike breast screening, where patients can self-refer once past screening age. In Scotland, screening is offered from 25-64 every five years.

In special situations, cervical screening in pregnancy is usually delayed until three months postpartum, unless there has been missed screening or previous abnormal smears. Women who have never been sexually active have a very low risk of developing cervical cancer and may wish to opt-out of screening.

While there is limited evidence to support it, the current advice given out by the NHS is that the best time to take a cervical smear is around mid-cycle. Understanding the cervical cancer screening program in the UK is crucial for women to take control of their health and prevent cervical cancer.

Pregnant women can generally fly safely if their pregnancy is progressing well, but it is important to check with the airline and insurance company before traveling. However, most airlines have restrictions on travel after 37 weeks of pregnancy or after 32 weeks for multiple pregnancies. Additionally, women over 28 weeks pregnant may need a letter from their doctor or midwife confirming their due date and good health. It is also recommended to bring along pregnancy notes when traveling.

The CAA has issued guidelines on air travel for people with medical conditions. Patients with certain cardiovascular diseases, uncomplicated myocardial infarction, coronary artery bypass graft, and percutaneous coronary intervention may fly after a certain period of time. Patients with respiratory diseases should be clinically improved with no residual infection before flying. Pregnant women may not be allowed to travel after a certain number of weeks and may require a certificate confirming the pregnancy is progressing normally. Patients who have had surgery should avoid flying for a certain period of time depending on the type of surgery. Patients with haematological disorders may travel without problems if their haemoglobin is greater than 8 g/dl and there are no coexisting conditions.

Annual Assessments for Women on Contraceptives

Women who use the combined contraceptive pill or the progesterone only pill should undergo an annual medical assessment to check for any new health issues. For those using the Depo-Provera injection, a review should be conducted every two years to evaluate the risks and benefits of the treatment.

The Mirena, an intrauterine device, can be used for up to seven years (off licence) if inserted when a woman is 45 years or older and if the patient is comfortable with their bleeding patterns. If a woman remains amenorrhoeic after seven years of use, the device can remain in place until menopause. Similarly, a copper coil inserted at the age of 40 years or over can be kept until menopause.

Regular assessments and reviews are crucial to ensure that women are receiving the most appropriate and effective contraceptive treatment for their individual needs. By staying up-to-date with their health status and treatment options, women can make informed decisions about their reproductive health and overall well-being.

Antihistamines are the preferred initial treatment for vomiting during pregnancy.

Specific Points for Antenatal Care

Antenatal care is an essential aspect of pregnancy, and NICE has issued guidelines on routine care for healthy pregnant women. Some specific points to consider during antenatal care include nausea and vomiting, vitamin D, and alcohol consumption.

For nausea and vomiting, natural remedies such as ginger and acupuncture on the ‘p6’ point are recommended by NICE. However, antihistamines such as promethazine are suggested as first-line treatment in the BNF.

Vitamin D is crucial for the health of both the mother and the baby. NICE recommends that all women should be informed about the importance of maintaining adequate vitamin D stores during pregnancy and breastfeeding. Women may choose to take 10 micrograms of vitamin D per day, as found in the Healthy Start multivitamin supplement. Women at risk, such as those who are Asian, obese, or have a poor diet, should take particular care.

Alcohol consumption during pregnancy can lead to long-term harm to the baby. In 2016, the Chief Medical Officer proposed new guidelines recommending that pregnant women should not drink alcohol at all. The official advice is to keep risks to the baby to a minimum, and the more alcohol consumed, the greater the risk.

In summary, antenatal care should include specific points such as managing nausea and vomiting, maintaining adequate vitamin D levels, and avoiding alcohol consumption during pregnancy. These guidelines aim to ensure the health and well-being of both the mother and the baby.

Women who have taken ulipristal acetate should wait for at least 5 days before starting regular hormonal contraception, according to current guidelines. This is because ulipristal acetate may decrease the effectiveness of hormonal contraception. Additionally, taking desogestrel hormonal contraception within 5 days of ulipristal acetate can also reduce the efficacy of emergency contraception. It is recommended to use additional precautions until contraceptive cover is re-established, and if desogestrel is being used, this should be after 48 hours. It would be helpful to discuss long-acting reversible contraception options with the patient in this case.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, and should be taken as soon as possible after unprotected sexual intercourse (UPSI) for maximum efficacy. The single dose of levonorgestrel is 1.5mg, but should be doubled for those with a BMI over 26 or weight over 70kg. It is safe and well-tolerated, but may cause vomiting in around 1% of women. Ulipristal, on the other hand, is a selective progesterone receptor modulator that inhibits ovulation. It should be taken within 120 hours after intercourse, and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which may inhibit fertilization or implantation. It must be inserted within 5 days of UPSI, or up to 5 days after the likely ovulation date. Prophylactic antibiotics may be given if the patient is at high-risk of sexually transmitted infection. The IUD is 99% effective regardless of where it is used in the cycle, and may be left in-situ for long-term contraception.

Postnatal depression affects approximately 1 in 7 women and its symptoms and effects are just as severe as depression at other times. While hormonal changes may contribute to postnatal depression, it is not the sole cause. Women who are breastfeeding can safely take most tricyclic antidepressants, except for doxepin, as long as their infant is healthy and being monitored. However, the use of St John’s wort is not recommended for breastfeeding mothers with depression.

Understanding Postpartum Mental Health Problems

Postpartum mental health problems can range from mild ‘baby-blues’ to severe puerperal psychosis. To screen for depression, healthcare professionals may use the Edinburgh Postnatal Depression Scale, which is a 10-item questionnaire that indicates how the mother has felt over the previous week. A score of over 13 indicates a ‘depressive illness of varying severity’, and the questionnaire includes a question about self-harm. The sensitivity and specificity of this screening tool are over 90%.

‘Baby-blues’ are seen in around 60-70% of women and typically occur 3-7 days following birth. This condition is more common in primips, and mothers are characteristically anxious, tearful, and irritable. Postnatal depression affects around 10% of women, with most cases starting within a month and typically peaking at 3 months. The features of postnatal depression are similar to depression seen in other circumstances.

Puerperal psychosis affects approximately 0.2% of women and usually occurs within the first 2-3 weeks following birth. The features of this condition include severe swings in mood (similar to bipolar disorder) and disordered perception (e.g. auditory hallucinations). Reassurance and support are important for all these conditions, but admission to hospital is usually required for puerperal psychosis, ideally in a Mother & Baby Unit. Cognitive behavioural therapy may be beneficial, and certain SSRIs such as sertraline and paroxetine may be used if symptoms are severe. While these medications are secreted in breast milk, they are not thought to be harmful to the infant. However, fluoxetine is best avoided due to its long half-life. There is around a 25-50% risk of recurrence following future pregnancies.

Women who are taking antiepileptic medication and are planning to conceive should be prescribed folic acid 5mg instead of the standard 400 mcg once daily. This high dose of folic acid should be taken from before conception until 12 weeks into the pregnancy to reduce the risk of neural tube defects. It is important to refer these women to a specialist for assessment, but they should continue to use effective contraception until then. It is important to reassure these women that they are likely to have a normal pregnancy and healthy baby. Folic acid should be started as soon as possible, even if the pregnancy is unplanned.

Folic Acid: Importance, Deficiency, and Prevention

Folic acid is a vital nutrient that is converted to tetrahydrofolate (THF) in the body. THF plays a crucial role in transferring 1-carbon units to essential substrates involved in DNA and RNA synthesis. Green, leafy vegetables are a good source of folic acid. However, certain medications like phenytoin and methotrexate, pregnancy, and alcohol excess can cause folic acid deficiency. This deficiency can lead to macrocytic, megaloblastic anemia and neural tube defects.

To prevent neural tube defects during pregnancy, all women should take 400mcg of folic acid until the 12th week of pregnancy. Women at higher risk of conceiving a child with a neural tube defect should take 5mg of folic acid from before conception until the 12th week of pregnancy. Women are considered higher risk if either partner has a neural tube defect, they have had a previous pregnancy affected by a neural tube defect, or they have a family history of a neural tube defect. Additionally, women with antiepileptic drugs or coeliac disease, diabetes, or thalassaemia trait, and those who are obese (BMI of 30 kg/m2 or more) are also at higher risk and should take the higher dose of folic acid.

If one COCP pill is missed, the patient should take the last pill as soon as possible, but no additional action is required.

The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their advice for women taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol. If one pill is missed at any time during the cycle, the woman should take the last pill, even if it means taking two pills in one day, and then continue taking pills daily, one each day. No additional contraceptive protection is needed. However, if two or more pills are missed, the woman should take the last pill, leave any earlier missed pills, and then continue taking pills daily, one each day. She should use condoms or abstain from sex until she has taken pills for seven days in a row. If pills are missed in week one, emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week one. If pills are missed in week two, after seven consecutive days of taking the COC, there is no need for emergency contraception. If pills are missed in week three, she should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of seven days on, seven days off.

It is safe to insert a contraceptive implant after childbirth, even immediately. However, the manufacturer of the most commonly used implant in the UK recommends waiting at least 4 weeks after childbirth for breastfeeding women. While there is no evidence of harm to the mother or baby, it is not recommended to insert an implant during pregnancy due to potential complications. It is important to note that fertility may not return until after the implant is removed.

Implanon and Nexplanon are both subdermal contraceptive implants that slowly release the hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is an updated version of Implanon with a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It doesn’t contain estrogen, making it suitable for women with a history of thromboembolism or migraines. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraception is required for the first 7 days if not inserted on days 1-5 of the menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs may reduce the efficacy of Nexplanon, and women should switch to a different method or use additional contraception until 28 days after stopping the treatment. Contraindications include ischaemic heart disease/stroke, unexplained vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Breast cancer is a UKMEC 4 condition, meaning it represents an unacceptable risk if the contraceptive method is used.

Folic Acid Requirements for Women During Pregnancy

Most women are advised to take 400 mcg of folic acid daily from before conception until week 12 of pregnancy. However, there are exceptions to this rule. Women who are at a higher risk of neural tube defects, such as those with a history of bearing children with NTDs, or women with diabetes or taking anticonvulsants, should take a higher dose of 5 mg daily from before conception until week 12 of pregnancy.

Another group of women who require a higher dose of folic acid are those with sickle cell disease. They need to take 5 mg of folic acid daily throughout pregnancy, and even when not pregnant, they’ll usually be taking folic acid 5 mg every 1 to 7 days, depending on the severity of their disease. It’s important for women to consult with their healthcare provider to determine the appropriate dose of folic acid for their individual needs during pregnancy.

Rachel began taking the progesterone only pill during the fourth day of her menstrual cycle, which means she will have instant protection since it was before the fifth day of her cycle.

Counselling for Women Considering the Progestogen-Only Pill

Women who are considering taking the progestogen-only pill (POP) should receive counselling on various aspects of the medication. One of the most common potential adverse effects is irregular vaginal bleeding. It is important to note that the POP should be taken at the same time every day, without a pill-free break, unlike the combined oral contraceptive (COC).

When starting the POP, immediate protection is provided if commenced up to and including day 5 of the cycle. If started later, additional contraceptive methods such as condoms should be used for the first 2 days. If switching from a COC, immediate protection is provided if continued directly from the end of a pill packet.

In case of missed pills, if the delay is less than 3 hours, the pill should be taken as usual. If the delay is more than 3 hours, the missed pill should be taken as soon as possible, and extra precautions such as condoms should be used until pill taking has been re-established for 48 hours.

It is important to note that antibiotics have no effect on the POP, unless the antibiotic alters the P450 enzyme system. Liver enzyme inducers may reduce the effectiveness of the POP. In case of diarrhoea and vomiting, the POP should be continued, but it should be assumed that pills have been missed.

Finally, it is important to discuss sexually transmitted infections (STIs) with healthcare providers when considering the POP. By providing comprehensive counselling, women can make informed decisions about whether the POP is the right contraceptive choice for them.

The contraceptive patch regime involves wearing one patch per week for three weeks, followed by a patch-free week. This method is gaining popularity due to its flexibility, as the patch can be changed up to 48 hours late without the need for extra contraception. Additionally, the patch’s transdermal absorption means that it is not affected by vomiting or diarrhea, eliminating the need for additional precautions. Similar to the pill, this method involves three weeks of contraception followed by a one-week break, during which the woman will experience a withdrawal bleed.

How to Use the Combined Contraceptive Patch

The Evra patch is the only combined contraceptive patch approved for use in the UK. It is worn for 3 weeks straight and then removed for a week, during which a withdrawal bleed occurs. If the patch is not changed on time, different rules apply depending on the week of the patch cycle.

If the patch change is delayed at the end of week 1 or week 2, it should be changed immediately. If the delay is less than 48 hours, no further precautions are needed. However, if the delay is greater than 48 hours, a barrier method of contraception should be used for the next 7 days. If unprotected sexual intercourse has occurred during this extended patch-free interval or in the last 5 days, emergency contraception should be considered.

If the patch removal is delayed at the end of week 3, it should be removed as soon as possible and a new patch applied on the usual cycle start day for the next cycle, even if withdrawal bleeding is occurring. No additional contraception is needed. If patch application is delayed at the end of a patch-free week, additional barrier contraception should be used for 7 days following any delay at the start of a new patch cycle.

For more information on combined hormonal methods of contraception, please refer to the NICE Clinical Knowledge Summary.

Breastfeeding women who follow a vegan diet may require a B12 supplement as this vitamin is primarily present in meat and dairy products. Vegans can obtain vitamin B12 from fortified breakfast cereals and yeast extracts like Marmite. Additionally, the NHS recommends that all breastfeeding women, regardless of their dietary preferences, should take a daily vitamin D supplement of 10 mcg to promote bone health for themselves and their baby. Women who are eligible for Healthy Start vouchers may receive free supplements, and their Health Visitor can provide guidance on this matter.

Vitamin B12 is a type of water-soluble vitamin that belongs to the B complex group. Unlike other vitamins, it can only be found in animal-based foods. The human body typically stores enough vitamin B12 to last for up to 5 years. This vitamin plays a crucial role in various bodily functions, including acting as a cofactor for the conversion of homocysteine into methionine through the enzyme homocysteine methyltransferase, as well as for the isomerization of methylmalonyl CoA to Succinyl Co A via the enzyme methylmalonyl mutase. Additionally, it is used to regenerate folic acid in the body.

However, there are several causes of vitamin B12 deficiency, including pernicious anaemia, Diphyllobothrium latum infection, and Crohn’s disease. When the body lacks vitamin B12, it can lead to macrocytic, megaloblastic anaemia and peripheral neuropathy. To prevent these consequences, it is important to ensure that the body has enough vitamin B12 through a balanced diet or supplements.

Breastfeeding is generally safe with most anti-epileptic drugs, including the commonly prescribed Lamotrigine. This drug is often preferred for women as it doesn’t affect their ability to bear children. However, Carbimazole and Diazepam’s active metabolite can be passed on to the baby through breast milk and should be avoided. Isotretinoin’s effect on breastfed infants is not well studied, but oral retinoids should generally be avoided while breastfeeding.

Pregnancy and breastfeeding can be a concern for women with epilepsy. It is generally recommended that women continue taking their medication during pregnancy, as the risks of uncontrolled seizures outweigh the potential risks to the fetus. However, it is important to aim for monotherapy and to take folic acid before pregnancy to reduce the risk of neural tube defects. The use of antiepileptic medication during pregnancy can increase the risk of congenital defects, with sodium valproate being associated with neural tube defects, carbamazepine being considered the least teratogenic of the older antiepileptics, and phenytoin being associated with cleft palate. Lamotrigine may be a safer option, but the dose may need to be adjusted during pregnancy. Breastfeeding is generally safe for mothers taking antiepileptics, except for barbiturates. Women taking phenytoin should be given vitamin K in the last month of pregnancy to prevent clotting disorders in the newborn. It is important to seek specialist neurological or psychiatric advice before starting or continuing antiepileptic medication during pregnancy or in women of childbearing age. Recent evidence has shown a significant risk of neurodevelopmental delay in children following maternal use of sodium valproate, leading to recommendations that it should not be used during pregnancy or in women of childbearing age unless absolutely necessary.

A cervical smear is not a diagnostic test and should only be conducted as a part of a screening program. An 18-year-old’s risk of cervical cancer is already low, and a normal vaginal examination can further reduce it.

If controlling bleeding is the goal, the combined oral contraceptive pill is more effective than the progesterone-only pill.

Implanon and Nexplanon are both subdermal contraceptive implants that slowly release the hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is an updated version of Implanon with a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It doesn’t contain estrogen, making it suitable for women with a history of thromboembolism or migraines. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraception is required for the first 7 days if not inserted on days 1-5 of the menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs may reduce the efficacy of Nexplanon, and women should switch to a different method or use additional contraception until 28 days after stopping the treatment. Contraindications include ischaemic heart disease/stroke, unexplained vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Breast cancer is a UKMEC 4 condition, meaning it represents an unacceptable risk if the contraceptive method is used.

It should be noted that the woman already had hypertension before becoming pregnant. Blood pressure issues related to pregnancy, such as pre-eclampsia or pregnancy-induced hypertension, typically do not occur until after 20 weeks of gestation. The fact that her ambulatory blood pressure readings were elevated rules out the possibility of her hypertension being caused by anxiety in a medical setting. It is important to consider the possibility of secondary hypertension, as high blood pressure in a woman of this age is not typical.

Hypertension during pregnancy is a common condition that can be managed effectively with proper care. In normal pregnancy, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, if a pregnant woman develops hypertension, it is usually defined as a systolic blood pressure of over 140 mmHg or a diastolic blood pressure of over 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from booking readings can also indicate hypertension.

After confirming hypertension, the patient should be categorized into one of three groups: pre-existing hypertension, pregnancy-induced hypertension (PIH), or pre-eclampsia. PIH, also known as gestational hypertension, occurs in 3-5% of pregnancies and is more common in older women. If a pregnant woman takes an ACE inhibitor or angiotensin II receptor blocker for pre-existing hypertension, it should be stopped immediately, and alternative antihypertensives should be started while awaiting specialist review.

Pregnancy-induced hypertension in association with proteinuria, which occurs in around 5% of pregnancies, may also cause oedema. The 2010 NICE guidelines recommend oral labetalol as the first-line treatment for hypertension during pregnancy. Oral nifedipine and hydralazine may also be used, depending on the patient’s medical history. It is important to manage hypertension during pregnancy effectively to reduce the risk of complications and ensure the health of both the mother and the baby.

Orlistat is a medication used to treat obesity by inhibiting gastrointestinal lipase and reducing fat absorption from the gut. However, it often causes loose stool or diarrhea unless the patient follows a low-fat diet. It is crucial to assess the suitability of orlistat for patients taking critical medications like antiepileptics and contraceptive pills, as it may decrease their effectiveness by increasing gut transit time. If the patient wants to continue taking orlistat, it is advisable to consider alternative contraception methods that are more reliable.

Obesity can be managed through a stepwise approach that includes conservative, medical, and surgical options. The first step is usually conservative, which involves implementing changes in diet and exercise. If this is not effective, medical options such as Orlistat may be considered. Orlistat is a pancreatic lipase inhibitor that is used to treat obesity. However, it can cause adverse effects such as faecal urgency/incontinence and flatulence. A lower dose version of Orlistat is now available without prescription, known as ‘Alli’. The National Institute for Health and Care Excellence (NICE) has defined criteria for the use of Orlistat. It should only be prescribed as part of an overall plan for managing obesity in adults who have a BMI of 28 kg/m^2 or more with associated risk factors, or a BMI of 30 kg/m^2 or more, and continued weight loss of at least 5% at 3 months. Orlistat is typically used for less than one year.

Tamoxifen Side Effects According to BNF

The British National Formulary (BNF) is often used to set questions for the AKT, and it lists the frequency of side effects for medications. Tamoxifen, for example, has common or very common side effects such as headaches, while all the other options are rare or very rare. Patients taking tamoxifen should be informed about the increased risk of thromboembolism and advised to watch for symptoms of DVT and PE. Additionally, patients should be warned about the increased risk of endometrial cancer and instructed to report any relevant symptoms. It is important for healthcare professionals to be aware of these potential side effects and counsel patients accordingly.

Missed Birth Control Pills

When it comes to missed birth control pills, most of the advice and evidence is based on studies of the 35 mcg oestrogen combined pill. However, it’s important to note that the risk of pregnancy with a missed 20 mcg pill may be higher than with a larger dose pill. Despite this, the Royal College of Obstetricians and Gynaecologists (RCOG) recommends that women take the missed pill and continue with the pack. Additional contraception is not required in this case.

If two or more pills are missed, it’s recommended to use barrier contraception for around seven days. It’s important to follow the instructions provided with your specific type of birth control pill and to speak with your healthcare provider if you have any concerns or questions.

Signs and Symptoms of Hyperprolactinaemia

This patient is presenting with several signs and symptoms of hyperprolactinaemia, including weight gain, loss of libido, menstrual disturbance, and galactorrhoea. While conditions such as PCOS, depression, and Cushing’s can cause weight gain and menstrual changes, galactorrhoea is only associated with pregnancy, prolactinoma, certain medications, and hypothyroidism.

It is important to note that the patient’s normal abdominal examination after ten months of amenorrhea, with her last sexual encounter occurring nine months prior, rules out pregnancy as a potential cause for her symptoms. Further investigation and testing may be necessary to determine the underlying cause of her hyperprolactinaemia.

Emergency contraception is necessary if unprotected sex occurred within 48 hours of restarting the POP after a missed pill. In this case, the patient missed her second pill by over 12 hours and is within the 48-hour window. A pregnancy test cannot provide reassurance the day after intercourse. It is important to take additional precautions and resume taking the medication at the normal time after a missed pill for 48 hours. If the missed pill is forgotten for 24 hours, taking two pills at once may be necessary, but it is not applicable in this scenario as the missed pill has already been taken.

The progestogen only pill (POP) has simpler rules for missed pills compared to the combined oral contraceptive pill. It is important to not confuse the two. For traditional POPs such as Micronor, Noriday, Norgeston, and Femulen, as well as Cerazette (desogestrel), if a pill is less than 3 hours late, no action is required and pill taking can continue as normal. However, if a pill is more than 3 hours late (i.e. more than 27 hours since the last pill was taken), action is needed. If a pill is less than 12 hours late, no action is required. But if a pill is more than 12 hours late (i.e. more than 36 hours since the last pill was taken), action is needed.

If action is needed, the missed pill should be taken as soon as possible. If more than one pill has been missed, only one pill should be taken. The next pill should be taken at the usual time, which may mean taking two pills in one day. Pill taking should continue with the rest of the pack. Extra precautions, such as using condoms, should be taken until pill taking has been re-established for 48 hours.

Cerazette: A Controversial Contraceptive Option

Cerazette is a popular contraceptive pill that has been marketed as having a Pearl Index similar to the combined pill. It is known for its ability to suppress ovulation and is suitable for a range of women. However, whether Cerazette is superior to traditional POPs is a topic of debate. Despite its effectiveness, Cerazette is not recommended as a first-line option due to its cost. It is only available on prescription and has a missed pill window of 12 hours.

Cerazette has a wider time frame for taking the pill than traditional progestogen only pills, but if a pill is missed, the user should take two pills immediately and use additional contraception for two days.

The progestogen only pill (POP) has simpler rules for missed pills compared to the combined oral contraceptive pill. It is important to not confuse the two. For traditional POPs such as Micronor, Noriday, Norgeston, and Femulen, as well as Cerazette (desogestrel), if a pill is less than 3 hours late, no action is required and pill taking can continue as normal. However, if a pill is more than 3 hours late (i.e. more than 27 hours since the last pill was taken), action is needed. If a pill is less than 12 hours late, no action is required. But if a pill is more than 12 hours late (i.e. more than 36 hours since the last pill was taken), action is needed.

If action is needed, the missed pill should be taken as soon as possible. If more than one pill has been missed, only one pill should be taken. The next pill should be taken at the usual time, which may mean taking two pills in one day. Pill taking should continue with the rest of the pack. Extra precautions, such as using condoms, should be taken until pill taking has been re-established for 48 hours.

Medication Protocol for Early Pregnancy

As soon as a pregnancy test comes back positive, it is recommended to prescribe aspirin 75 mg. This medication can help prevent blood clots and other complications during pregnancy. Once foetal heart activity is detected on an ultrasound scan, low dose self-administered subcutaneous heparin should be started. This medication can also help prevent blood clots and is especially important for women who have a history of blood clots or other risk factors. It is important to follow this medication protocol to ensure the health and safety of both the mother and the developing foetus.

Breakthrough Bleeding on Combined Oral Contraceptive

In patients experiencing breakthrough bleeding while on the combined oral contraceptive, it is crucial to check their compliance and potential illness. However, if these factors are not the cause, breakthrough bleeding may indicate an alternative issue and prompt further investigation for gynaecological causes. This is especially true for patients who have been taking the pill for an extended period.

To assess potential gynaecological causes, a pelvic examination and swabs are necessary. It is also important to ensure that the patient’s smear is up-to-date and to take one if overdue. While cervical cancer is rare in this age group, swabs should be taken to check for chlamydial cervicitis, the most common cause of breakthrough bleeding in young sexually active women.

Additionally, it is crucial to consider the possibility of pregnancy and perform a pregnancy test. However, in cases where compliance and regular usage of the combined pill are confirmed, the likelihood of pregnancy is remote. Proper investigation and assessment can help identify the underlying cause of breakthrough bleeding and ensure appropriate treatment.

A family history doesn’t pose any contraindications for COCP use and is classified as UKMEC 1. However, being a known BRCA1/2 gene carrier is classified as UKMEC 3 for COCP use. If a person has a current breast cancer diagnosis, it is classified as UKMEC 4. If the breast cancer diagnosis was more than 5 years ago, it is classified as UKMEC 3.

Contraindications for Combined Oral Contraceptive Pill

The decision to prescribe the combined oral contraceptive pill is based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential cautions and contraindications on a four-point scale. UKMEC 1 represents a condition for which there is no restriction for the use of the contraceptive method, while UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, immobility, and a family history of thromboembolic disease in first-degree relatives under 45 years old. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension.

In 2016, the UKMEC was updated to reflect that breastfeeding between 6 weeks and 6 months postpartum is now classified as UKMEC 2 instead of UKMEC 3. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. It is important for healthcare providers to consider these contraindications when deciding whether to prescribe the combined oral contraceptive pill to their patients.

If a person has a BMI over 26 kg/m2 or weighs over 70 kg, the recommended dose of levonorgestrel should be doubled from 1.5 mg to 3 mg, not 6 mg. Ulipristal acetate is contraindicated for those with brittle asthma that is controlled with glucocorticoids. It would be incorrect to inform the patient that she is not at risk of pregnancy as she is still at risk.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, and should be taken as soon as possible after unprotected sexual intercourse (UPSI) for maximum efficacy. The single dose of levonorgestrel is 1.5mg, but should be doubled for those with a BMI over 26 or weight over 70kg. It is safe and well-tolerated, but may cause vomiting in around 1% of women. Ulipristal, on the other hand, is a selective progesterone receptor modulator that inhibits ovulation. It should be taken within 120 hours after intercourse, and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which may inhibit fertilization or implantation. It must be inserted within 5 days of UPSI, or up to 5 days after the likely ovulation date. Prophylactic antibiotics may be given if the patient is at high-risk of sexually transmitted infection. The IUD is 99% effective regardless of where it is used in the cycle, and may be left in-situ for long-term contraception.

If pre-eclampsia is suspected in a woman, NICE recommends arranging emergency secondary care assessment. This is because pre-eclampsia can be life-threatening and may not present with obvious symptoms. In this case, the patient has high blood pressure and proteinuria, which are signs of pre-eclampsia. While a growth scan may be necessary later, it is not the priority now. Home BP monitoring is also not indicated at this stage. Instead, the patient needs further investigation and management by obstetric specialists. Labetalol may be used to manage her blood pressure, but only after specialist input.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, age over 40, high BMI, family history of pre-eclampsia, and multiple pregnancy. To reduce the risk of hypertensive disorders in pregnancy, women with high or moderate risk factors should take aspirin daily. Management involves emergency assessment, admission for severe cases, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

Women who have taken ulipristal acetate should wait for 5 days before beginning regular hormonal contraception. It is crucial to note that the effectiveness of EllaOne decreases if progestogen is used within 5 days after taking it. Therefore, it is essential to start hormonal contraceptives 5 days after taking EllaOne. Starting the combined oral contraceptive pill at the same time or less than 5 days after taking EllaOne would be incorrect. It is a misconception that EllaOne is only effective if the combined oral contraceptive pill has already been started. Taking EllaOne 14 days after the start of the last menstrual period is also incorrect. The copper coil could be inserted as an effective form of contraception 5 days after the expected date of ovulation, but EllaOne must be taken within 5 days of unprotected sexual intercourse.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, and should be taken as soon as possible after unprotected sexual intercourse (UPSI) for maximum efficacy. The single dose of levonorgestrel is 1.5mg, but should be doubled for those with a BMI over 26 or weight over 70kg. It is safe and well-tolerated, but may cause vomiting in around 1% of women. Ulipristal, on the other hand, is a selective progesterone receptor modulator that inhibits ovulation. It should be taken within 120 hours after intercourse, and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which may inhibit fertilization or implantation. It must be inserted within 5 days of UPSI, or up to 5 days after the likely ovulation date. Prophylactic antibiotics may be given if the patient is at high-risk of sexually transmitted infection. The IUD is 99% effective regardless of where it is used in the cycle, and may be left in-situ for long-term contraception.

Monitoring hCG Levels After Molar Pregnancy

After a molar pregnancy, it is important to monitor hCG levels to detect any persistent gestational trophoblastic disease (GTD) that may require treatment. During this monitoring period, women should avoid becoming pregnant as it is difficult to differentiate between hCG levels that are increasing due to a new pregnancy or persistent GTD. The first hCG measurement is taken four weeks after uterine evacuation.

For complete hydatidiform mole, hCG monitoring is required for six months from the first normal hCG level or six months from evacuation of the uterus if the hCG level normalizes by eight weeks after evacuation. On the other hand, partial molar pregnancy has a lower risk of persistent GTD, and hCG follow-up is only necessary until two consecutive monthly levels are normal.

If a woman undergoes chemotherapy for gestational trophoblastic neoplasia, she should avoid pregnancy for at least one year. It is crucial to monitor hCG levels after molar pregnancy to ensure early detection and treatment of any persistent GTD.

If a woman has a history of STI, it is advisable to refer her to secondary care earlier. For women under 36 years of age, referral for further assessment and management should be considered if they have not conceived after one year, and their history, examination, and investigations are normal. However, if the woman is 36 years or older, has amenorrhea or oligomenorrhea, previous abdominal or pelvic surgery, previous pelvic inflammatory disease, abnormal pelvic examination, or a known reason for infertility, earlier referral should be considered. Similarly, for men, referral should be considered earlier if they have a history of previous genital pathology, urogenital surgery, STI, varicocele, significant systemic illness, abnormal genital examination, or a known reason for infertility.

Understanding Infertility: Initial Investigations and Key Counselling Points

Infertility is a common issue that affects approximately 1 in 7 couples. However, it is important to note that around 84% of couples who have regular sex will conceive within 1 year, and 92% within 2 years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

To determine the cause of infertility, basic investigations are typically conducted. These include a semen analysis and a serum progesterone test, which is done 7 days prior to the expected next period. The interpretation of the serum progesterone level is as follows: if the level is less than 16 nmol/l, it should be repeated and if it consistently remains low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

In addition to these investigations, there are key counselling points that should be addressed. These include advising the patient to take folic acid, aiming for a BMI between 20-25, and having regular sexual intercourse every 2 to 3 days. Patients should also be advised to quit smoking and limit alcohol consumption.

By understanding the initial investigations and key counselling points for infertility, healthcare professionals can provide their patients with the necessary information and support to help them conceive.

Best Time for Cervical Smear

According to the NHS Cervical Screening Programme, the best time for women to have their cervical smear is mid-cycle, usually 14 days from the start of their last period. This timing allows for a clearer background to the sample, as the mucous plug is at its thinnest and the epithelium is at its thickest, resulting in a full range of cells being obtained. However, this is not a strict rule, and women should not be deterred from having their cervical smear if they cannot get an appointment at this time. It is important to seek advice from a doctor or practice nurse if needed.

Breastfeeding women can safely take SSRIs such as sertraline or paroxetine as the amount of antidepressant passed on to the infant through breast milk is very low and not considered harmful. Therefore, it is recommended that women with postnatal depression continue to breastfeed while receiving antidepressant treatment.

Understanding Postpartum Mental Health Problems

Postpartum mental health problems can range from mild ‘baby-blues’ to severe puerperal psychosis. To screen for depression, healthcare professionals may use the Edinburgh Postnatal Depression Scale, which is a 10-item questionnaire that indicates how the mother has felt over the previous week. A score of over 13 indicates a ‘depressive illness of varying severity’, and the questionnaire includes a question about self-harm. The sensitivity and specificity of this screening tool are over 90%.

‘Baby-blues’ are seen in around 60-70% of women and typically occur 3-7 days following birth. This condition is more common in primips, and mothers are characteristically anxious, tearful, and irritable. Postnatal depression affects around 10% of women, with most cases starting within a month and typically peaking at 3 months. The features of postnatal depression are similar to depression seen in other circumstances.

Puerperal psychosis affects approximately 0.2% of women and usually occurs within the first 2-3 weeks following birth. The features of this condition include severe swings in mood (similar to bipolar disorder) and disordered perception (e.g. auditory hallucinations). Reassurance and support are important for all these conditions, but admission to hospital is usually required for puerperal psychosis, ideally in a Mother & Baby Unit. Cognitive behavioural therapy may be beneficial, and certain SSRIs such as sertraline and paroxetine may be used if symptoms are severe. While these medications are secreted in breast milk, they are not thought to be harmful to the infant. However, fluoxetine is best avoided due to its long half-life. There is around a 25-50% risk of recurrence following future pregnancies.

Benefits of Breastfeeding

Breastfeeding has been shown to have numerous benefits for both the mother and the baby. According to the National Institute for Health and Clinical Excellence (NICE) Promotion of breastfeeding initiation and duration (2006), breastfeeding can help reduce the incidence of various conditions.

Studies have demonstrated that breastfeeding can reduce the risk of infantile gastroenteritis, urinary tract infections, atopic disease, juvenile insulin-dependent diabetes mellitus, respiratory infections, and otitis media. However, it is important to note that breastfeeding may not necessarily protect against other conditions such as ADHD, intussusception, or rickets.

Overall, breastfeeding is a natural and effective way to promote the health and well-being of both the mother and the baby.

When women use an IUS for endometrial protection as part of their HRT regimen, they need to replace the device every 4 years according to the BNF or 5 years according to the FSRH. The Mirena® IUS is effective in protecting the endometrium from the effects of exogenous estrogen, and the BNF recommends its use for this purpose. However, if the Mirena® IUS is used for contraception and inserted after the age of 45, it can remain in place until menopause, even if the woman is still having periods.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

Emergency Contraception Options After Childbirth

Oral levonorgestrel 1.5 mg and ulipristal acetate 30 mg are safe to use 21 days after childbirth, while the copper intrauterine device can be used for emergency contraception from day 28 postpartum. Among the three options, the copper intrauterine device is the most effective, with a pregnancy rate of approximately 1 in 1000.

It is important to note that the copper intrauterine device carries the same contraindications as when used for standard contraception. It can be retained until the next period then removed or kept in situ for ongoing long-term contraception. With these options available, women can make informed decisions about their reproductive health after childbirth.

Injectable Contraceptives: Depo Provera

Injectable contraceptives are a popular form of birth control in the UK, with Depo Provera being the main option available. This contraceptive contains 150 mg of medroxyprogesterone acetate and is administered via intramuscular injection every 12 weeks. It can be given up to 14 weeks after the last dose without the need for extra precautions. The primary method of action is by inhibiting ovulation, while secondary effects include cervical mucous thickening and endometrial thinning.

However, there are some disadvantages to using Depo Provera. Once the injection is given, it cannot be reversed, and there may be a delayed return to fertility of up to 12 months. Adverse effects may include irregular bleeding and weight gain, and there is a potential increased risk of osteoporosis. It should only be used in adolescents if no other method of contraception is suitable.

It is important to note that Noristerat, another injectable contraceptive licensed in the UK, is rarely used in clinical practice. It is given every 8 weeks. The BNF gives different advice regarding the interval between injections, stating that a pregnancy test should be done if the interval is greater than 12 weeks and 5 days. However, this is not commonly adhered to in the family planning community.

Hyperemesis gravidarum is a severe form of nausea and vomiting that affects around 1% of pregnancies. It is usually experienced between 8 and 12 weeks of pregnancy but can persist up to 20 weeks. The condition is thought to be related to raised beta hCG levels and is more common in women who are obese, nulliparous, or have multiple pregnancies, trophoblastic disease, or hyperthyroidism. Smoking is associated with a decreased incidence of hyperemesis.

The Royal College of Obstetricians and Gynaecologists recommend that a woman must have a 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance before a diagnosis of hyperemesis gravidarum can be made. Validated scoring systems such as the Pregnancy-Unique Quantification of Emesis (PUQE) score can be used to classify the severity of NVP.

Management of hyperemesis gravidarum involves using antihistamines as a first-line treatment, with oral cyclizine or oral promethazine being recommended by Clinical Knowledge Summaries. Oral prochlorperazine is an alternative, while ondansetron and metoclopramide may be used as second-line treatments. Ginger and P6 (wrist) acupressure can be tried, but there is little evidence of benefit. Admission may be needed for IV hydration.

Complications of hyperemesis gravidarum can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth restriction, preterm birth, and cleft lip/palate (if ondansetron is used during the first trimester). The NICE Clinical Knowledge Summaries recommend considering admission if a woman is unable to keep down liquids or oral antiemetics, has ketonuria and/or weight loss (greater than 5% of body weight), or has a confirmed or suspected comorbidity that may be adversely affected by nausea and vomiting.

Effects of Smoking During Pregnancy

Smoking during pregnancy has various effects on both the mother and the developing fetus. One positive effect is that pre-eclampsia, a potentially life-threatening condition characterized by high blood pressure and damage to organs, is less likely to occur in smokers. However, there is an increased rate of spontaneous abortion and intrauterine growth may be retarded. Additionally, smoking increases the risk of prematurity, which can lead to various health complications for the baby. There is also an increase in perinatal mortality over the average, meaning that the risk of the baby dying before or shortly after birth is higher. Furthermore, smoking during pregnancy increases the risk of thromboembolism, a condition where a blood clot forms and blocks a blood vessel, which can be fatal for both the mother and the baby. Therefore, it is highly recommended for pregnant women to quit smoking to ensure the best possible outcomes for both themselves and their babies.

Requests for personal data are not typically covered by the Freedom of Information Act 2000. The Patient Records Act 2007 is not a real law.

Understanding the Data Protection Act

The Data Protection Act is a crucial piece of legislation that governs the protection of personal data in the UK. It applies to both manual and computerised records and outlines eight main principles that entities must follow. These principles include using data for its intended purpose, obtaining consent before disclosing data to other parties, allowing individuals access to their personal information, keeping data up-to-date and secure, and correcting any factual errors.

In 2018, the Data Protection Act was updated to include new provisions such as the right to erasure, exemptions, and regulation in conjunction with the GDPR. It is important for all entities that process personal information to register with the Information Commissioner’s Office and implement adequate security measures to protect sensitive data. By following the principles outlined in the Data Protection Act, entities can ensure that they are handling personal information in a responsible and ethical manner.

Antiphospholipid Syndrome: A Cause of Recurrent Miscarriage

Antiphospholipid syndrome is a medical condition that can lead to recurrent miscarriage. It can also present as arterial or venous thrombosis, livedo reticularis rash, stroke, adrenal hemorrhage, migraine, myelitis, myocardial infarction, or multi-infarct dementia. Anticardiolipin antibodies may be found in patients with this syndrome. Venous thrombi occur more often if lupus anticoagulant is positive, while arterial thrombi occur if IgG or IgM antiphospholipid antibody are positive. Long-term warfarin is indicated for treatment.

Initially, it was believed that up to 30% of SLE sufferers had antiphospholipid syndrome. However, it is now thought that primary antiphospholipid syndrome is a separate entity consisting of a tendency to thrombosis, positive antiphospholipid antibodies, but the absence of clinical features of SLE. It is important to recognize and diagnose this syndrome early to prevent complications such as recurrent miscarriage and thrombosis.

Understanding Primary Hyperparathyroidism

Hyperparathyroidism is a common disorder among elderly females that can cause hypercalcaemia with a borderline low phosphate concentration and a minimally elevated parathyroid hormone (PTH) concentration. However, it is important to note that PTH may be elevated or inappropriately normal in primary hyperparathyroidism, which can make diagnosis tricky.

Other conditions that can cause hypercalcaemia include bony metastases, multiple myeloma, and PTH related peptide in malignancy. However, these conditions should result in a suppressed PTH or a low PTH that is not detected by normal lab tests.

If the hypercalcaemia is caused by multiple myeloma, a physiological decrease in PTH would be expected as a response. In the case of primary hyperparathyroidism, the inappropriately normal PTH should lead to a diagnosis. It is important to consider all possible causes and understand the nuances of PTH levels in order to accurately diagnose and treat hyperparathyroidism.

Managing Menopause: Lifestyle Modifications, HRT, and Non-HRT Options

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is diagnosed when a woman has not had a period for 12 months. Menopausal symptoms are common and can last for several years. The management of menopause can be divided into three categories: lifestyle modifications, hormone replacement therapy (HRT), and non-hormone replacement therapy.

Lifestyle modifications can help manage symptoms such as hot flashes, sleep disturbance, mood changes, and cognitive symptoms. Regular exercise, weight loss, stress reduction, and good sleep hygiene are recommended.

HRT is an effective treatment for menopausal symptoms, but it is not suitable for everyone. Women with current or past breast cancer, any oestrogen-sensitive cancer, undiagnosed vaginal bleeding, or untreated endometrial hyperplasia should not take HRT. HRT brings certain risks, including an increased risk of venous thromboembolism, stroke, coronary heart disease, breast cancer, and ovarian cancer.

Non-HRT options include fluoxetine, citalopram, or venlafaxine for vasomotor symptoms, vaginal lubricants or moisturisers for vaginal dryness, self-help groups, cognitive behaviour therapy, or antidepressants for psychological symptoms, and vaginal oestrogen for urogenital symptoms.

When stopping HRT, it is important to gradually reduce the dosage to limit recurrence in the short term. Women should be referred to secondary care if treatment has been ineffective, if there are ongoing side effects, or if there is unexplained bleeding.

Disorders of Sex Development: Common Conditions and Characteristics

Disorders of sex development refer to a group of conditions that affect the development of an individual’s reproductive system. The most common disorders are androgen insensitivity syndrome, 5-α reductase deficiency, male and female pseudohermaphroditism, and true hermaphroditism. Androgen insensitivity syndrome is an X-linked recessive condition that results in end-organ resistance to testosterone, causing genotypically male children to have a female phenotype. 5-α reductase deficiency, on the other hand, is an autosomal recessive condition that results in the inability of males to convert testosterone to dihydrotestosterone, leading to ambiguous genitalia in the newborn period. Male and female pseudohermaphroditism are conditions where individuals have testes or ovaries but external genitalia are female or male, respectively. Finally, true hermaphroditism is a very rare condition where both ovarian and testicular tissue are present. Understanding the characteristics of these conditions is crucial in providing appropriate medical care and support for affected individuals.

Treatment options for urge incontinence

Caffeine reduction is the first recommended therapy for patients with significant urge incontinence and a history of excessive caffeine use. If symptoms persist, bladder training is the next step. For those who do not respond to bladder training, oxybutynin may be effective. In postmenopausal women with significant vaginal atrophy, oestrogen cream may also be tried. However, electrical stimulation is not routinely recommended. It is important to consult with a healthcare professional to determine the best treatment plan for individual cases of urge incontinence.

If two pills are missed during week 3 of taking the COCP, it is important to finish the current pack of pills and immediately start a new pack without taking the pill-free interval. This is necessary to prevent ovulation and the risk of pregnancy. It is not recommended to finish the current pack and start a new pack after the pill-free interval as this could lead to ovulation and pregnancy. Emergency contraception is not necessary in this situation as long as ovulation has not yet occurred. The copper coil, ulipristal, and levonorgestrel are all forms of emergency contraception and are not appropriate in this scenario.

The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their advice for women taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol. If one pill is missed at any time during the cycle, the woman should take the last pill, even if it means taking two pills in one day, and then continue taking pills daily, one each day. No additional contraceptive protection is needed. However, if two or more pills are missed, the woman should take the last pill, leave any earlier missed pills, and then continue taking pills daily, one each day. She should use condoms or abstain from sex until she has taken pills for seven days in a row. If pills are missed in week one, emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week one. If pills are missed in week two, after seven consecutive days of taking the COC, there is no need for emergency contraception. If pills are missed in week three, she should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of seven days on, seven days off.

Nancy can be advised that she doesn’t need contraception for up to 21 days after giving birth. According to the Faculty of Sexual and Reproductive Healthcare Guideline on Postnatal Sexual and Reproductive Health, contraceptive protection is not necessary before Day 21 postpartum. However, if Nancy wants to avoid pregnancy after Day 21, she should use a contraceptive method as ovulation may occur as early as Day 28 in non-breastfeeding women. Breastfeeding women who want to prevent pregnancy should also use a contraceptive method, although any method will be more effective due to reduced fertility. Fully breastfeeding women may rely on the lactational amenorrhoea method (LAM) alone until breastfeeding decreases or other LAM criteria are no longer met.

After giving birth, women need to use contraception after 21 days. The Progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first 2 days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the Combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than 6 weeks postpartum. If breastfeeding is between 6 weeks to 6 months postpartum, it is UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk postpartum. After day 21, additional contraception should be used for the first 7 days.

The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after 4 weeks. Meanwhile, the Lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than 6 months postpartum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Medication Use During Pregnancy: Risks and Considerations

Valproic Acid, Mirtazapine, Haloperidol, Lithium, and Olanzapine are all medications used to treat various mental health conditions. However, when it comes to using these medications during pregnancy, there are important considerations and potential risks to be aware of.

Valproic Acid, for example, is highly teratogenic and should not be used to treat bipolar disorder during pregnancy. The risk to the fetus outweighs the benefit to the mother, and there are safer alternative mood stabilizers available. Mirtazapine, on the other hand, should be used with caution during pregnancy, and the neonate must be monitored for any withdrawal effects. Haloperidol use during the third trimester has been associated with neonatal extrapyramidal side effects and withdrawal. Lithium is associated with an increased risk of cardiac abnormalities in the fetus, especially if taken during the first trimester. Finally, while there is not a known increased risk of neural tube defects with Olanzapine use during pregnancy, there is a risk of the neonate developing extrapyramidal side effects or withdrawal symptoms.

It is important for pregnant individuals to discuss any medication use with their healthcare provider to weigh the potential risks and benefits and make informed decisions about their treatment.

The use of ondansetron during pregnancy has been associated with an increased risk of 3 oral clefts per 10,000 births, according to a study. However, this risk is not included in the RCOG guideline on nausea and vomiting of pregnancy, and there is no official NICE guidance on the matter. A draft of NICE’s antenatal care guidance suggests that ondansetron may increase the chance of a baby being born with a cleft lip or palate, but there are no recognised risks for the mother or newborn. Claims of a risk of spontaneous miscarriage in twin pregnancies or severe congenital heart defects in newborns are not supported by current evidence.

Hyperemesis gravidarum is a severe form of nausea and vomiting that affects around 1% of pregnancies. It is usually experienced between 8 and 12 weeks of pregnancy but can persist up to 20 weeks. The condition is thought to be related to raised beta hCG levels and is more common in women who are obese, nulliparous, or have multiple pregnancies, trophoblastic disease, or hyperthyroidism. Smoking is associated with a decreased incidence of hyperemesis.

The Royal College of Obstetricians and Gynaecologists recommend that a woman must have a 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance before a diagnosis of hyperemesis gravidarum can be made. Validated scoring systems such as the Pregnancy-Unique Quantification of Emesis (PUQE) score can be used to classify the severity of NVP.

Management of hyperemesis gravidarum involves using antihistamines as a first-line treatment, with oral cyclizine or oral promethazine being recommended by Clinical Knowledge Summaries. Oral prochlorperazine is an alternative, while ondansetron and metoclopramide may be used as second-line treatments. Ginger and P6 (wrist) acupressure can be tried, but there is little evidence of benefit. Admission may be needed for IV hydration.

Complications of hyperemesis gravidarum can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth restriction, preterm birth, and cleft lip/palate (if ondansetron is used during the first trimester). The NICE Clinical Knowledge Summaries recommend considering admission if a woman is unable to keep down liquids or oral antiemetics, has ketonuria and/or weight loss (greater than 5% of body weight), or has a confirmed or suspected comorbidity that may be adversely affected by nausea and vomiting.

A fundamental comprehension of physiology is necessary to comprehend contraception, gynaecological disorders, and fertility issues, as progesterone is produced by the corpus luteum after ovulation, despite the AKT having limited inquiries about it.

Phases of the Menstrual Cycle

The menstrual cycle is a complex process that can be divided into four phases: menstruation, follicular phase, ovulation, and luteal phase. During the follicular phase, a number of follicles develop in the ovaries, with one follicle becoming dominant around the mid-follicular phase. At the same time, the endometrium undergoes proliferation. This phase is characterized by a rise in follicle-stimulating hormone (FSH), which results in the development of follicles that secrete oestradiol. When the egg has matured, it secretes enough oestradiol to trigger the acute release of luteinizing hormone (LH), which leads to ovulation.

During the luteal phase, the corpus luteum secretes progesterone, which causes the endometrium to change to a secretory lining. If fertilization doesn’t occur, the corpus luteum will degenerate, and progesterone levels will fall. Oestradiol levels also rise again during the luteal phase. Cervical mucous thickens and forms a plug across the external os following menstruation. Just prior to ovulation, the mucous becomes clear, acellular, low viscosity, and stretchy. Under the influence of progesterone, it becomes thick, scant, and tacky. Basal body temperature falls prior to ovulation due to the influence of oestradiol and rises following ovulation in response to higher progesterone levels. Understanding the phases of the menstrual cycle is important for women’s health and fertility.

UK Medical Eligibility Criteria for Contraception

The UK medical eligibility criteria for contraception categorizes contraceptive methods into four categories. Category 1 indicates that there are no restrictions for use, while Category 4 indicates that use poses an unacceptable health risk. For patients with a BRCA gene mutation, the combined contraceptive pill has a UK Category rating of 3 and should definitely not be used. All of the other options are rated a UK Category 2, so will still need careful follow-up. The intrauterine copper coil is the only method that is rated a UK Category 1, making it the safest option to use here. There is no restriction on the use of this method for this condition. It is important to consider the UK medical eligibility criteria when choosing a contraceptive method to ensure the safety and effectiveness of the chosen method.

When a pregnant woman is exposed to Chickenpox, it can lead to serious complications for both her and the developing fetus. To prevent this, the first step is to check the woman’s immune status by testing for varicella antibodies. If she is found to be non-immune, she should receive varicella-zoster immune globulin (VZIG) as soon as possible for post-exposure prophylaxis (PEP).

It is important to note that the management and organization of the blood test can be arranged by the GP, although the midwife should also be informed. If the woman is less than 20 weeks pregnant and non-immune, VZIG should be given immediately, but it may still be effective up to 10 days after exposure.

For pregnant women who develop Chickenpox after 20 weeks of gestation, oral aciclovir or an equivalent antiviral should be started within 24 hours of rash onset. However, if the woman is less than 20 weeks pregnant, it is recommended to seek specialist advice.

It is crucial to take action and not simply provide reassurance in cases where the woman is found to be non-immune to varicella, as both she and the fetus are at risk.

Chickenpox Exposure in Pregnancy: Risks and Management

Chickenpox is caused by the varicella-zoster virus and can pose risks to both the mother and fetus during pregnancy. The mother is at a five times greater risk of pneumonitis, while the fetus is at risk of developing fetal varicella syndrome (FVS) if the mother is exposed to Chickenpox before 20 weeks gestation. FVS can result in skin scarring, eye defects, limb hypoplasia, microcephaly, and learning disabilities. There is also a risk of shingles in infancy and severe neonatal varicella if the mother develops a rash between 5 days before and 2 days after birth.

To manage Chickenpox exposure in pregnancy, post-exposure prophylaxis (PEP) may be necessary. If the pregnant woman is not immune to varicella, VZIG or antivirals may be given within 10 days of exposure. Waiting until days 7-14 is recommended to reduce the risk of developing clinical varicella. However, the decision on choice of PEP for women exposed from 20 weeks of pregnancy should take into account patient and health professional preference as well as the ability to offer and provide PEP in a timely manner.

If a pregnant woman develops Chickenpox, specialist advice should be sought. Oral aciclovir may be given if the pregnant woman is ≥ 20 weeks and presents within 24 hours of onset of the rash. However, caution should be exercised if the woman is < 20 weeks. Overall, managing Chickenpox exposure in pregnancy requires careful consideration of the risks and benefits to both the mother and fetus.

Acne Medications and Pregnancy: Risks and Precautions

Acne is a common skin condition that affects many people, including pregnant women. However, not all acne medications are safe to use during pregnancy. Here are some important things to know about the risks and precautions of using acne medications during pregnancy.

Isotretinoin is a highly effective medication for reducing sebum secretion, but it is also highly teratogenic. Women who take isotretinoin must have a negative pregnancy test before treatment and use effective contraception during and after the course. Congenital deafness and central nervous system and heart defects may occur in children exposed to isotretinoin in utero.

Topical retinoids, such as topical isotretinoin and topical retinoin, have a very low absorption rate through the skin. However, there are some reports of birth defects associated with their use, so women should avoid using them during pregnancy until more data is collected.

Clindamycin, a topical and systemic antibiotic, has no reported adverse effects in pregnancy. Minocycline and oxytetracycline are less effective for acne treatment but are also less teratogenic. However, tetracyclines can stain bones and teeth, so they should be stopped if pregnancy occurs. Erythromycin is a more suitable antibiotic for pregnant women with acne.

In summary, pregnant women with acne should consult with their healthcare provider before using any acne medication. It is important to weigh the potential risks and benefits of each medication and take appropriate precautions to ensure the safety of both the mother and the fetus.

A hydatidiform mole is characterized by painless vaginal bleeding. High levels of hCG may cause symptoms of thyrotoxicosis, which can mimic thyroid stimulating hormone.

Gestational trophoblastic disorders refer to a range of conditions that originate from the placental trophoblast. These disorders include complete hydatidiform mole, partial hydatidiform mole, and choriocarcinoma. Complete hydatidiform mole is a benign tumor of trophoblastic material that occurs when an empty egg is fertilized by a single sperm that duplicates its own DNA, resulting in all 46 chromosomes being of paternal origin. Symptoms of this disorder include bleeding in the first or early second trimester, exaggerated pregnancy symptoms, a large uterus for dates, and high levels of human chorionic gonadotropin (hCG) in the blood. Hypertension and hyperthyroidism may also be present. Urgent referral to a specialist center is necessary, and evacuation of the uterus is performed. Effective contraception is recommended to avoid pregnancy in the next 12 months. About 2-3% of cases may progress to choriocarcinoma. In partial mole, a normal haploid egg may be fertilized by two sperms or one sperm with duplication of paternal chromosomes, resulting in DNA that is both maternal and paternal in origin. Fetal parts may be visible, and the condition is usually triploid.

It is recommended that all women with a BMI greater than 30 undergo screening for gestational diabetes using an oral glucose tolerance test (OGTT) between 24-28 weeks of pregnancy. Additionally, women who have risk factors for gestational diabetes, such as a family history of diabetes, a previous large baby weighing 4.5 kg or more, or belonging to an ethnic group with a high prevalence of diabetes, should also be offered an OGTT during this time. If a woman has previously had gestational diabetes, she should be offered an OGTT as soon as possible after booking and again at 24-28 weeks if the first test is normal. Alternatively, early self-monitoring of blood glucose may be offered as an option.

Gestational diabetes is a common medical disorder that affects around 4% of pregnancies. It can develop during pregnancy or be a pre-existing condition. According to NICE, 87.5% of cases are gestational diabetes, 7.5% are type 1 diabetes, and 5% are type 2 diabetes. Risk factors for gestational diabetes include a BMI of > 30 kg/m², previous gestational diabetes, a family history of diabetes, and family origin with a high prevalence of diabetes. Screening for gestational diabetes involves an oral glucose tolerance test (OGTT), which should be performed as soon as possible after booking and at 24-28 weeks if the first test is normal.

To diagnose gestational diabetes, NICE recommends using the following thresholds: fasting glucose is >= 5.6 mmol/L or 2-hour glucose is >= 7.8 mmol/L. Newly diagnosed women should be seen in a joint diabetes and antenatal clinic within a week and taught about self-monitoring of blood glucose. Advice about diet and exercise should be given, and if glucose targets are not met within 1-2 weeks of altering diet/exercise, metformin should be started. If glucose targets are still not met, insulin should be added to the treatment plan.

For women with pre-existing diabetes, weight loss is recommended for those with a BMI of > 27 kg/m^2. Oral hypoglycaemic agents, apart from metformin, should be stopped, and insulin should be commenced. Folic acid 5 mg/day should be taken from preconception to 12 weeks gestation, and a detailed anomaly scan at 20 weeks, including four-chamber view of the heart and outflow tracts, should be performed. Tight glycaemic control reduces complication rates, and retinopathy should be treated as it can worsen during pregnancy.

Targets for self-monitoring of pregnant women with diabetes include a fasting glucose level of 5.3 mmol/l and a 1-hour or 2-hour glucose level after meals of 7.8 mmol/l or 6.4 mmol/l, respectively. It is important to manage gestational diabetes and pre-existing diabetes during pregnancy to reduce the risk of complications for both the mother and baby.

All pregnant women are now advised to take 10mcg of vitamin D throughout their pregnancy. Additionally, low dose folic acid is recommended for the first 12 weeks of pregnancy for all women. However, those with pregnancies at a higher risk of neural tube defects should take 5mg of folic acid during the first 12 weeks. This includes couples where either partner has a neural tube defect or a family history of such defects, those who have had a previous pregnancy affected by a neural tube defect, or women with coeliac disease, diabetes mellitus, sickle-cell anaemia, or who are taking antiepileptic medication.

Vitamin D supplementation has been a topic of interest for several years, and recent releases have provided some clarity on the matter. The Chief Medical Officer’s 2012 letter and the National Osteoporosis Society’s 2013 UK Vitamin D guideline recommend that certain groups take vitamin D supplements. These groups include pregnant and breastfeeding women, children aged 6 months to 5 years, adults over 65 years, and individuals who are not exposed to much sun, such as housebound patients.

Testing for vitamin D deficiency is not necessary for most people. The NOS guidelines suggest that testing may be appropriate for patients with bone diseases that may be improved with vitamin D treatment, such as osteomalacia or Paget’s disease, and for patients with musculoskeletal symptoms that could be attributed to vitamin D deficiency, such as bone pain. However, patients with osteoporosis should always be given calcium/vitamin D supplements, and individuals at higher risk of vitamin D deficiency should be treated regardless of testing. Overall, vitamin D supplementation is recommended for certain groups, while testing for deficiency is only necessary in specific situations.

Understanding Parity and Its Relationship with Gravity

Parity refers to the number of pregnancies a woman has had that have been carried to a viable age, which is typically 24 weeks in the UK. This number is represented by a digit followed by a plus sign and another digit, which indicates the number of pregnancies that did not reach viability. Essentially, parity reflects the number of babies a woman has given birth to, while gravida refers to the number of times a woman’s uterus has contained a fetus, regardless of whether the pregnancy resulted in a live birth.

It’s worth noting that parity only increases once a baby is born, whereas gravida increases from conception. For instance, if a woman has given birth to twins, her parity would be 2, while her gravida would be 1. Understanding the difference between parity and gravida is important for healthcare providers to accurately assess a woman’s obstetric history and provide appropriate care.

Most pathologists hold the view that uterine leiomyosarcomas, which may appear as ‘fibroids’ at first, are most likely new growths rather than a conversion of pre-existing fibroids.

Understanding Uterine Fibroids

Uterine fibroids are non-cancerous growths that develop in the uterus. They are more common in black women and are believed to occur in around 20% of white women in their later reproductive years. Fibroids are usually asymptomatic, but they can cause menorrhagia, which can lead to iron-deficiency anaemia. Other symptoms include lower abdominal pain, bloating, and urinary symptoms. Fibroids may also cause subfertility, but this is rare.

Diagnosis is usually done through transvaginal ultrasound. Asymptomatic fibroids do not require treatment, but periodic monitoring is necessary. For menorrhagia, treatment options include the levonorgestrel intrauterine system, NSAIDs, tranexamic acid, oral progestogen, and injectable progestogen. Medical treatment to shrink or remove fibroids includes GnRH agonists and ulipristal acetate, while surgical options include myomectomy, hysteroscopic endometrial ablation, hysterectomy, and uterine artery embolization.

Fibroids generally regress after menopause, and complications such as subfertility and iron-deficiency anaemia have been mentioned previously. Another complication is red degeneration, which is haemorrhage into the tumour and commonly occurs during pregnancy. Understanding uterine fibroids is important for women’s health, and seeking medical attention is necessary if symptoms arise.

The effectiveness of the progesterone only pill can be achieved within 48 hours of starting it, regardless of the time in the menstrual cycle it is initiated.

Counselling for Women Considering the Progestogen-Only Pill

Women who are considering taking the progestogen-only pill (POP) should receive counselling on various aspects of the medication. One of the most common potential adverse effects is irregular vaginal bleeding. It is important to note that the POP should be taken at the same time every day, without a pill-free break, unlike the combined oral contraceptive (COC).

When starting the POP, immediate protection is provided if commenced up to and including day 5 of the cycle. If started later, additional contraceptive methods such as condoms should be used for the first 2 days. If switching from a COC, immediate protection is provided if continued directly from the end of a pill packet.

In case of missed pills, if the delay is less than 3 hours, the pill should be taken as usual. If the delay is more than 3 hours, the missed pill should be taken as soon as possible, and extra precautions such as condoms should be used until pill taking has been re-established for 48 hours.

It is important to note that antibiotics have no effect on the POP, unless the antibiotic alters the P450 enzyme system. Liver enzyme inducers may reduce the effectiveness of the POP. In case of diarrhoea and vomiting, the POP should be continued, but it should be assumed that pills have been missed.

Finally, it is important to discuss sexually transmitted infections (STIs) with healthcare providers when considering the POP. By providing comprehensive counselling, women can make informed decisions about whether the POP is the right contraceptive choice for them.

Pregnant women with a BMI of ≥30 kg/m² should be prescribed a high dose of 5mg folic acid to help prevent neural tube defects (NTD) in the first trimester of pregnancy. This is in addition to patients with diabetes, sickle cell disease (SCD), thalassaemia trait, coeliac disease, on anti-epileptic medication, personal or family history of NTD, or who have previously given birth to a baby with an NTD. Folic acid should ideally be started before conception to further reduce the risk of NTD.

However, a history of asthma, smoking, patient age, and Asian ethnicity are not indications for high-dose folic acid prescribing in pregnancy. Smoking during pregnancy can increase the risk of prematurity, low birth weight, and cleft lip/palate, but there is currently no recommendation for high-dose folic acid prescribing for pregnant smokers. While asthma and extreme maternal age may carry some NTD risk, there is no current recommendation for high-dose folic acid prescribing for these patient groups.

In addition to folic acid, all pregnant patients should take vitamin D 10mcg (400 units) daily throughout their entire pregnancy, according to NICE guidelines.

Folic Acid: Importance, Deficiency, and Prevention

Folic acid is a vital nutrient that is converted to tetrahydrofolate (THF) in the body. THF plays a crucial role in transferring 1-carbon units to essential substrates involved in DNA and RNA synthesis. Green, leafy vegetables are a good source of folic acid. However, certain medications like phenytoin and methotrexate, pregnancy, and alcohol excess can cause folic acid deficiency. This deficiency can lead to macrocytic, megaloblastic anemia and neural tube defects.

To prevent neural tube defects during pregnancy, all women should take 400mcg of folic acid until the 12th week of pregnancy. Women at higher risk of conceiving a child with a neural tube defect should take 5mg of folic acid from before conception until the 12th week of pregnancy. Women are considered higher risk if either partner has a neural tube defect, they have had a previous pregnancy affected by a neural tube defect, or they have a family history of a neural tube defect. Additionally, women with antiepileptic drugs or coeliac disease, diabetes, or thalassaemia trait, and those who are obese (BMI of 30 kg/m2 or more) are also at higher risk and should take the higher dose of folic acid.

Understanding Postpartum Depression

Postpartum depression is a common condition that affects many new mothers. It typically occurs within a year of childbirth and is characterized by a range of symptoms, including feelings of sadness, anxiety, and hopelessness. While some women may experience a short-lived reaction known as the baby blues, postnatal depression typically begins within two to three months of giving birth and can last for several months or even longer.

If you are experiencing symptoms of postpartum depression, it is important to seek help from a healthcare professional. Treatment options may include therapy, medication, or a combination of both. With the right support and treatment, it is possible to overcome postpartum depression and enjoy a healthy, happy life with your new baby.

If a pregnant woman who is not immune to Chickenpox is exposed to the virus, it is recommended to seek specialist advice. Varicella-zoster immunoglobulin (VZIG) can be effective in preventing Chickenpox if given within 10 days of exposure. However, in this scenario, the woman is already 16 weeks pregnant and aciclovir should only be given to women over 20 weeks gestation within 24 hours of rash onset. As the patient has already developed Chickenpox, VZIG would not be appropriate.

Chickenpox during pregnancy can lead to serious complications for both the mother and the fetus, including pneumonitis and fetal varicella syndrome (FVS) if contracted before 28 weeks gestation. Therefore, offering reassurance alone is not sufficient in this case. While there is no indication that the patient is unwell enough to require emergency care, appropriate safety-netting should be provided due to the risk of severe complications.

Chickenpox Exposure in Pregnancy: Risks and Management

Chickenpox is caused by the varicella-zoster virus and can pose risks to both the mother and fetus during pregnancy. The mother is at a five times greater risk of pneumonitis, while the fetus is at risk of developing fetal varicella syndrome (FVS) if the mother is exposed to Chickenpox before 20 weeks gestation. FVS can result in skin scarring, eye defects, limb hypoplasia, microcephaly, and learning disabilities. There is also a risk of shingles in infancy and severe neonatal varicella if the mother develops a rash between 5 days before and 2 days after birth.

To manage Chickenpox exposure in pregnancy, post-exposure prophylaxis (PEP) may be necessary. If the pregnant woman is not immune to varicella, VZIG or antivirals may be given within 10 days of exposure. Waiting until days 7-14 is recommended to reduce the risk of developing clinical varicella. However, the decision on choice of PEP for women exposed from 20 weeks of pregnancy should take into account patient and health professional preference as well as the ability to offer and provide PEP in a timely manner.

If a pregnant woman develops Chickenpox, specialist advice should be sought. Oral aciclovir may be given if the pregnant woman is ≥ 20 weeks and presents within 24 hours of onset of the rash. However, caution should be exercised if the woman is < 20 weeks. Overall, managing Chickenpox exposure in pregnancy requires careful consideration of the risks and benefits to both the mother and fetus.

While the absolute number of ectopic pregnancies is decreased, the proportion of pregnancies that are ectopic is increased with the use of IUCD.

New intrauterine contraceptive devices include the Jaydess® IUS and Kyleena® IUS. The Jaydess® IUS is licensed for 3 years and has a smaller frame, narrower inserter tube, and less levonorgestrel than the Mirena® coil. The Kyleena® IUS has 19.5mg LNG, is smaller than the Mirena®, and is licensed for 5 years. Both result in lower serum levels of LNG, but the rate of amenorrhoea is less with Kyleena® compared to Mirena®.

To prevent birth defects, it is recommended to steer clear of ACE inhibitors and angiotensin-2 receptor blockers. Instead, many healthcare providers opt to prescribe methyldopa or labetalol as the initial treatment for this condition.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, age over 40, high BMI, family history of pre-eclampsia, and multiple pregnancy. To reduce the risk of hypertensive disorders in pregnancy, women with high or moderate risk factors should take aspirin daily. Management involves emergency assessment, admission for severe cases, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

The copper intrauterine device can be used as emergency contraception within 5 days after the first unprotected sexual intercourse in a cycle or within 5 days of the estimated date of ovulation, whichever is later. It’s important to note that pregnancy can occur at any time during the menstrual cycle after unprotected sex. Levonorgestrel is approved for emergency contraception up to 72 hours after intercourse, while ulipristal acetate is approved for up to 120 hours after intercourse. Since the patient is still within 5 days of ovulation on day 16 of her regular cycle, the copper intrauterine device can be used as emergency contraception. There is no indication that the patient is pregnant and requires termination.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, and should be taken as soon as possible after unprotected sexual intercourse (UPSI) for maximum efficacy. The single dose of levonorgestrel is 1.5mg, but should be doubled for those with a BMI over 26 or weight over 70kg. It is safe and well-tolerated, but may cause vomiting in around 1% of women. Ulipristal, on the other hand, is a selective progesterone receptor modulator that inhibits ovulation. It should be taken within 120 hours after intercourse, and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which may inhibit fertilization or implantation. It must be inserted within 5 days of UPSI, or up to 5 days after the likely ovulation date. Prophylactic antibiotics may be given if the patient is at high-risk of sexually transmitted infection. The IUD is 99% effective regardless of where it is used in the cycle, and may be left in-situ for long-term contraception.

HELLP Syndrome: A Dangerous Condition in Pregnant Women

HELLP syndrome is a serious condition that can occur in pregnant women who have pre-eclampsia or eclampsia. It is characterized by liver damage and abnormalities in blood clotting, which can lead to serious complications for both the mother and the baby.

The symptoms of HELLP syndrome include hypertension, right upper quadrant/epigastric pain, sickness/vomiting, and oedema. Haemolysis can cause anaemia and increase bilirubin levels, while elevated liver enzymes and low platelet counts are also common.

It’s important to note that even mild elevations in blood pressure can lead to HELLP syndrome in some cases. Pregnant women with a diastolic BP of 90 or more should be evaluated for a hypertensive disorder of pregnancy. Additionally, changes in blood pressure should be monitored closely, as a significant rise in diastolic or systolic BP can be a warning sign of HELLP syndrome.

Overall, early detection and treatment of HELLP syndrome is crucial for the health and safety of both the mother and the baby. If you are pregnant and experiencing any of the symptoms associated with HELLP syndrome, it’s important to seek medical attention right away.

The risk of expulsion for intrauterine contraceptive devices is 1 in 20 during the first 3 months, making it the most common reason for IUD failure. Therefore, it is crucial to check the threads after every menstrual cycle.

New intrauterine contraceptive devices include the Jaydess® IUS and Kyleena® IUS. The Jaydess® IUS is licensed for 3 years and has a smaller frame, narrower inserter tube, and less levonorgestrel than the Mirena® coil. The Kyleena® IUS has 19.5mg LNG, is smaller than the Mirena®, and is licensed for 5 years. Both result in lower serum levels of LNG, but the rate of amenorrhoea is less with Kyleena® compared to Mirena®.

Hepatitis B and Pregnancy: Screening and Prevention

During pregnancy, all women are offered screening for hepatitis B. If a woman is found to be chronically infected with hepatitis B or has had acute hepatitis B during pregnancy, her baby should receive a complete course of vaccination and hepatitis B immunoglobulin. Studies are currently being conducted to evaluate the effectiveness of oral antiviral treatment, such as Lamivudine, in the latter part of pregnancy.

There is little evidence to suggest that a caesarean section reduces the transmission rates of hepatitis B from mother to baby. It is important to note that hepatitis B cannot be transmitted through breastfeeding, unlike HIV. Therefore, mothers with hepatitis B can safely breastfeed their babies without fear of transmission.

Overall, screening for hepatitis B during pregnancy and taking appropriate preventative measures can greatly reduce the risk of transmission from mother to baby. It is important for healthcare providers to educate pregnant women about the importance of screening and prevention to ensure the health and safety of both mother and baby.

During pregnancy, there is an increase in the levels of thyroxine-binding globulin (TBG), which causes an increase in the levels of total thyroxine. However, this doesn’t affect the free thyroxine level. If left untreated, thyrotoxicosis can increase the risk of fetal loss, maternal heart failure, and premature labor. Graves’ disease is the most common cause of thyrotoxicosis during pregnancy, but transient gestational hyperthyroidism can also occur due to the activation of the TSH receptor by HCG. Propylthiouracil has traditionally been the antithyroid drug of choice, but it is associated with an increased risk of severe hepatic injury. Therefore, NICE Clinical Knowledge Summaries recommend using propylthiouracil in the first trimester and switching to carbimazole in the second trimester. Maternal free thyroxine levels should be kept in the upper third of the normal reference range to avoid fetal hypothyroidism. Thyrotrophin receptor stimulating antibodies should be checked at 30-36 weeks gestation to determine the risk of neonatal thyroid problems. Block-and-replace regimens should not be used in pregnancy, and radioiodine therapy is contraindicated.

On the other hand, thyroxine is safe during pregnancy, and serum thyroid-stimulating hormone should be measured in each trimester and 6-8 weeks postpartum. Women require an increased dose of thyroxine during pregnancy, up to 50% as early as 4-6 weeks of pregnancy. Breastfeeding is safe while on thyroxine. It is important to manage thyroid problems during pregnancy to ensure the health of both the mother and the baby.

Management of Bleeding in Early Pregnancy

When a woman experiences bleeding in early pregnancy, it is important to follow the appropriate management guidelines. According to NICE advice, if bleeding settles before 6 weeks of gestation and the woman is haemodynamically stable and pain-free, a repeat pregnancy test should be done after 7-10 days to determine if a miscarriage has occurred. Follow-up should also be arranged to manage any changes in the clinical situation, with safety netting advice provided.

Immediate referral to hospital is not necessary in this scenario, unless the patient becomes haemodynamically unstable. A serum βHCG test is also not required as a urinary pregnancy test has already been conducted and is positive. It is important to provide follow-up to ensure that the patient’s symptoms do not worsen and to check for a possible miscarriage.

If a woman is less than 6 weeks pregnant and experiences bleeding but no pain, referral to an EPU is only necessary if bleeding continues after 6 weeks gestation or if symptoms of an ectopic pregnancy develop. In this case, the patient’s bleeding has settled, she is haemodynamically stable, and there are no symptoms of an ectopic pregnancy.

If a couple has a history of neural tube defects (NTDs), either partner has a NTD, or they have a family history of NTDs, they are at high risk of conceiving a child with this condition. Additionally, if the woman has coeliac disease, diabetes, thalassaemia trait, or is taking antiepileptic drugs, the risk is also increased. However, being obese (with a BMI of 30 kg/m2 or more) is not a risk factor for NTDs and may actually be protective. On the other hand, advancing maternal age is a known risk factor for Down’s syndrome, while maternal rubella can lead to multiple congenital malformations and mental retardation in the child.

Folic Acid: Importance, Deficiency, and Prevention

Folic acid is a vital nutrient that is converted to tetrahydrofolate (THF) in the body. THF plays a crucial role in transferring 1-carbon units to essential substrates involved in DNA and RNA synthesis. Green, leafy vegetables are a good source of folic acid. However, certain medications like phenytoin and methotrexate, pregnancy, and alcohol excess can cause folic acid deficiency. This deficiency can lead to macrocytic, megaloblastic anemia and neural tube defects.

To prevent neural tube defects during pregnancy, all women should take 400mcg of folic acid until the 12th week of pregnancy. Women at higher risk of conceiving a child with a neural tube defect should take 5mg of folic acid from before conception until the 12th week of pregnancy. Women are considered higher risk if either partner has a neural tube defect, they have had a previous pregnancy affected by a neural tube defect, or they have a family history of a neural tube defect. Additionally, women with antiepileptic drugs or coeliac disease, diabetes, or thalassaemia trait, and those who are obese (BMI of 30 kg/m2 or more) are also at higher risk and should take the higher dose of folic acid.

The 2015 BHIVA guidelines suggest that patients should commence HAART immediately upon HIV diagnosis, irrespective of pregnancy status, rather than delaying until a specific CD4 count, as was previously advised.

HIV and Pregnancy: Guidelines for Minimizing Vertical Transmission

With the increasing prevalence of HIV infection among heterosexual individuals, there has been a rise in the number of HIV-positive women giving birth in the UK. In London, the incidence may be as high as 0.4% of pregnant women. The goal of treating HIV-positive women during pregnancy is to minimize harm to both the mother and fetus and to reduce the chance of vertical transmission.

To achieve this goal, various factors must be considered. Guidelines on this subject are regularly updated, and the most recent guidelines can be found using the links provided. Factors that can reduce vertical transmission from 25-30% to 2% include maternal antiretroviral therapy, mode of delivery (caesarean section), neonatal antiretroviral therapy, and infant feeding (bottle feeding).

To ensure that HIV-positive women receive appropriate care during pregnancy, NICE guidelines recommend offering HIV screening to all pregnant women. Additionally, all pregnant women should be offered antiretroviral therapy, regardless of whether they were taking it previously.

The mode of delivery is also an important consideration. Vaginal delivery is recommended if the viral load is less than 50 copies/ml at 36 weeks. Otherwise, a caesarean section is recommended, and a zidovudine infusion should be started four hours before beginning the procedure.

Neonatal antiretroviral therapy is also crucial in minimizing vertical transmission. Zidovudine is usually administered orally to the neonate if the maternal viral load is less than 50 copies/ml. Otherwise, triple ART should be used, and therapy should be continued for 4-6 weeks.

Finally, infant feeding is another important factor to consider. In the UK, all women should be advised not to breastfeed to minimize the risk of vertical transmission. By following these guidelines, healthcare providers can help minimize the risk of vertical transmission and ensure that HIV-positive women receive appropriate care during pregnancy.

Navigating Personal Beliefs in Medical Practice: Handling Conflicts with Duty of Care in Termination of Pregnancy

As healthcare professionals, doctors are bound by their duty of care to provide appropriate medical treatment to their patients. However, personal beliefs can sometimes come into conflict with this duty, particularly in cases of termination of pregnancy. The General Medical Council’s Good Medical Practice (2013) allows doctors to practice medicine in accordance with their beliefs, as long as they do not treat patients unfairly, deny them access to appropriate medical treatment or services, or cause them distress.

If a doctor’s personal beliefs prevent them from facilitating onward care for a patient seeking termination of pregnancy, there are several options available. The doctor can gently explain their conscientious objection to the procedure, but must not delay appropriate treatment or cause the patient distress. They can decline to continue with the consultation, but must still fully assess the patient’s needs and signpost them to another clinician for review if necessary. Alternatively, they can complete the consultation and refer the patient for termination of pregnancy, ensuring that the patient is treated fairly and respectfully and signposted to another clinician who can help.

Regardless of the chosen course of action, the doctor must not express disapproval of the patient’s choice or imply judgment of their lifestyle, choices, or beliefs. It is important to navigate personal beliefs in medical practice with sensitivity and respect for the patient’s autonomy and well-being.

Understanding Hirsutism and its Common Causes

Hirsutism is a condition characterized by excessive hair growth in women, often in areas where hair is typically absent or minimal. The most common cause of hirsutism is polycystic ovary syndrome (PCOS), which accounts for 95% of cases. This condition is often accompanied by obesity and amenorrhea, which are indicative of insulin resistance.

Biochemically, patients with PCOS have a reversed luteinising hormone:follicle-stimulating hormone (LH:FSH) ratio and elevated androstenedione with a low sex-hormone-binding globulin (SHBG). It is important to rule out other potential causes of hirsutism, such as androgen-producing tumors of the adrenal gland or ovary, Cushing’s syndrome, or congenital adrenal hyperplasia.

In summary, hirsutism is a common condition in women, with PCOS being the most common cause. Proper evaluation and diagnosis are crucial to ensure appropriate treatment and management.

Understanding Menorrhagia: Its Causes and Definition

Menorrhagia is a condition characterized by heavy menstrual bleeding. While it was previously defined as total blood loss exceeding 80 ml per menstrual cycle, the assessment and management of this condition now focuses on the woman’s perception of excessive bleeding and its impact on her quality of life. Menorrhagia can be caused by various factors, including dysfunctional uterine bleeding, anovulatory cycles, uterine fibroids, hypothyroidism, pelvic inflammatory disease, and bleeding disorders such as von Willebrand disease.

Dysfunctional uterine bleeding is the most common cause of menorrhagia, accounting for about half of all cases. It refers to heavy menstrual bleeding in the absence of any underlying pathology. Anovulatory cycles, on the other hand, are more common in women at the extremes of their reproductive life. Uterine fibroids, which are noncancerous growths in the uterus, can also cause menorrhagia. Hypothyroidism, a condition where the thyroid gland doesn’t produce enough hormones, can lead to heavy menstrual bleeding as well. Pelvic inflammatory disease, an infection of the female reproductive organs, can also cause menorrhagia. Finally, bleeding disorders such as von Willebrand disease, which affects the blood’s ability to clot, can also lead to heavy menstrual bleeding.

It is important to note that the intrauterine device (IUD) is not a cause of menorrhagia. In fact, the intrauterine system (Mirena) is used to treat menorrhagia. Understanding the causes of menorrhagia is crucial in its management and treatment.

The Caldicott guardian is responsible for safeguarding patient information.

The Role of Caldicott Guardians in Ensuring Patient Data Security

The Caldicott Report of 1997 highlighted the inadequacies in the management of confidential patient data in some parts of the NHS. To address this issue, the report recommended the appointment of Caldicott Guardians, who are responsible for ensuring the security of patient data.

Caldicott Guardians are members of staff who are tasked with overseeing the handling of confidential patient information within their respective NHS organizations. They are responsible for ensuring that patient data is kept secure and that access to it is restricted only to those who have a legitimate need to know.

Today, it is mandatory for every NHS organization to have a Caldicott Guardian. This requirement is in place to ensure that patient data is protected from unauthorized access, theft, or misuse. By appointing Caldicott Guardians, the NHS is taking proactive steps to safeguard the privacy and confidentiality of patient information, which is essential for maintaining trust and confidence in the healthcare system.

The use of Warfarin during breastfeeding is deemed to be safe.

Breastfeeding Contraindications: Drugs and Other Factors to Consider

Breastfeeding is generally recommended for infants as it provides numerous benefits for both the baby and the mother. However, there are certain situations where breastfeeding may not be advisable. One of the major contraindications is the use of certain drugs by the mother, which can be harmful to the baby. Antibiotics like penicillins and cephalosporins, as well as endocrine medications like levothyroxine, can be given to breastfeeding mothers. On the other hand, drugs like ciprofloxacin, tetracycline, and benzodiazepines should be avoided.

Aside from drugs, other factors like galactosaemia and viral infections can also make breastfeeding inadvisable. In the case of HIV, some doctors believe that the benefits of breastfeeding outweigh the risk of transmission, especially in areas where infant mortality and morbidity rates are high.

It is important for healthcare professionals to be aware of these contraindications and to provide appropriate guidance to mothers who are considering breastfeeding. By doing so, they can help ensure the health and well-being of both the mother and the baby.

Pregnancies that occur after the first childbirth are at the highest risk of complications if the mother was sensitized during the initial delivery. To mitigate this risk, the BCSH recommends that cord blood be tested for ABO and Rh D typing after birth. If the baby is confirmed to be D positive, all previously non-sensitized women who are D negative should be offered a minimum of 500 IU of anti-D Ig within 72 hours of delivery. Maternal samples should also be tested for FMH, and additional doses of anti-D Ig should be administered as indicated by the FMH test results.

Rhesus negative mothers can develop anti-D IgG antibodies if they deliver a Rh +ve child, which can cause haemolysis in future pregnancies. Prevention involves testing for D antibodies and giving anti-D prophylaxis at 28 and 34 weeks. Anti-D should also be given in various situations, such as delivery of a Rh +ve infant or amniocentesis. Tests include cord blood FBC, blood group, direct Coombs test, and Kleihauer test. Affected fetuses may experience oedema, jaundice, anaemia, hepatosplenomegaly, heart failure, and kernicterus, and may require transfusions and UV phototherapy.

Contraception and the BNF

Contraception questions are frequently asked in exams, and the British National Formulary (BNF) is a valuable resource for examiners. Many previous exam questions have focused on knowledge of contraindications and important adverse reactions.

According to the BNF, jaundice is a reason to immediately stop taking the combined oral contraceptive pill. Other reasons to stop taking the pill immediately include sudden severe chest pain, sudden breathlessness, and blood pressure above 160/100.

The other conditions listed are all cautions and would not warrant stopping the pill in isolation. However, if two or more cautions are present, there may be a need to stop taking the pill. It is important to be aware of these guidelines when prescribing or taking contraception.

If a woman is fully or almost fully breastfeeding, under 6 months postpartum, and not experiencing periods yet, lactational amenorrhoea can be a highly effective form of contraception. The UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) recommends that if these conditions are met, there may be no need for an alternative contraceptive method at this time.

After giving birth, women need to use contraception after 21 days. The Progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first 2 days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the Combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than 6 weeks postpartum. If breastfeeding is between 6 weeks to 6 months postpartum, it is UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk postpartum. After day 21, additional contraception should be used for the first 7 days.

The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after 4 weeks. Meanwhile, the Lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than 6 months postpartum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Before providing nicotine replacement therapy (NRT), it is recommended to conduct cognitive behavioral therapy (CBT) or motivational interviewing with pregnant women who smoke. Additionally, it is important to screen all pregnant women for smoking using a carbon monoxide monitor.

Smoking cessation is the process of quitting smoking. In 2008, NICE released guidance on how to manage smoking cessation. The guidance recommends that patients should be offered nicotine replacement therapy (NRT), varenicline or bupropion, and that clinicians should not favour one medication over another. These medications should be prescribed as part of a commitment to stop smoking on or before a particular date, and the prescription should only last until 2 weeks after the target stop date. If unsuccessful, a repeat prescription should not be offered within 6 months unless special circumstances have intervened. NRT can cause adverse effects such as nausea and vomiting, headaches, and flu-like symptoms. NICE recommends offering a combination of nicotine patches and another form of NRT to people who show a high level of dependence on nicotine or who have found single forms of NRT inadequate in the past.

Varenicline is a nicotinic receptor partial agonist that should be started 1 week before the patient’s target date to stop. The recommended course of treatment is 12 weeks, but patients should be monitored regularly and treatment only continued if not smoking. Varenicline has been shown in studies to be more effective than bupropion, but it should be used with caution in patients with a history of depression or self-harm. Nausea is the most common adverse effect, and varenicline is contraindicated in pregnancy and breastfeeding.

Bupropion is a norepinephrine and dopamine reuptake inhibitor, and nicotinic antagonist that should be started 1 to 2 weeks before the patient’s target date to stop. There is a small risk of seizures, and bupropion is contraindicated in epilepsy, pregnancy, and breastfeeding. Having an eating disorder is a relative contraindication.

In 2010, NICE recommended that all pregnant women should be tested for smoking using carbon monoxide detectors. All women who smoke, or have stopped smoking within the last 2 weeks, or those with a CO reading of 7 ppm or above should be referred to NHS Stop Smoking Services. The first-line interventions in pregnancy should be cognitive behaviour therapy, motivational interviewing, or structured self-help and support from NHS Stop Smoking Services. The evidence for the use of NRT in pregnancy is mixed, but it is often used if the above measures fail. There is no evidence that it affects the child’s birthweight. Pregnant women

No action is required as she has missed only one pill. For more details, please refer to the FSRH guidelines.

The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their advice for women taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol. If one pill is missed at any time during the cycle, the woman should take the last pill, even if it means taking two pills in one day, and then continue taking pills daily, one each day. No additional contraceptive protection is needed. However, if two or more pills are missed, the woman should take the last pill, leave any earlier missed pills, and then continue taking pills daily, one each day. She should use condoms or abstain from sex until she has taken pills for seven days in a row. If pills are missed in week one, emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week one. If pills are missed in week two, after seven consecutive days of taking the COC, there is no need for emergency contraception. If pills are missed in week three, she should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of seven days on, seven days off.

NICE doesn’t recommend routine auscultation for the fetal heart, but if the mother requests it, it may provide reassurance.

Antenatal care is an important aspect of pregnancy, and the National Institute for Health and Care Excellence (NICE) has issued guidelines on routine care for healthy pregnant women. The guidelines recommend 10 antenatal visits for first pregnancies and 7 visits for subsequent pregnancies, provided that the pregnancy is uncomplicated. Women do not need to see a consultant if their pregnancy is uncomplicated.

The timetable for antenatal visits begins with a booking visit between 8-12 weeks, where general information is provided on topics such as diet, alcohol, smoking, folic acid, vitamin D, and antenatal classes. Blood and urine tests are also conducted to check for conditions such as hepatitis B, syphilis, and asymptomatic bacteriuria. An early scan is conducted between 10-13+6 weeks to confirm dates and exclude multiple pregnancies, while Down’s syndrome screening is conducted between 11-13+6 weeks.

At 16 weeks, women receive information on the anomaly and blood results, and if their haemoglobin levels are below 11 g/dl, they may be advised to take iron supplements. Routine care is conducted at 18-20+6 weeks, including an anomaly scan, and at 25, 28, 31, and 34 weeks, where blood pressure, urine dipstick, and symphysis-fundal height (SFH) are checked. Women who are rhesus negative receive anti-D prophylaxis at 28 and 34 weeks.

At 36 weeks, presentation is checked, and external cephalic version may be offered if indicated. Information on breastfeeding, vitamin K, and ‘baby-blues’ is also provided. Routine care is conducted at 38 weeks, and at 40 weeks (for first pregnancies), discussion about options for prolonged pregnancy takes place. At 41 weeks, labour plans and the possibility of induction are discussed. The RCOG advises that either a single-dose or double-dose regime of anti-D prophylaxis can be used, depending on local factors.

Premature Ovarian Insufficiency: Causes, Symptoms, and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flashes, night sweats, infertility, secondary amenorrhoea, and elevated FSH and LH levels. Hormone replacement therapy or a combined oral contraceptive pill is recommended until the age of the average menopause, which is 51 years. It is important to note that HRT doesn’t provide contraception in case spontaneous ovarian activity resumes.

Systemic Methotrexate for Tubal Ectopic Pregnancy

According to RCOG Green top guideline No. 21, systemic methotrexate is a viable option for treating tubal ectopic pregnancy. This drug has been found to be equally successful as laparoscopic surgery in certain cases. However, it is crucial to first rule out an intrauterine pregnancy before administering methotrexate.

One advantage of using methotrexate is that it doesn’t affect ovarian reserve. However, women undergoing treatment should avoid alcohol and folate-containing vitamins. Additionally, it is recommended that women avoid pregnancy for at least three months after receiving methotrexate due to its teratogenic potential. This is because the drug may remain present in some organs for an extended period of time, which could potentially harm fetal development.

Hypertension during pregnancy is a common condition that can be managed effectively with proper care. In normal pregnancy, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, if a pregnant woman develops hypertension, it is usually defined as a systolic blood pressure of over 140 mmHg or a diastolic blood pressure of over 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from booking readings can also indicate hypertension.

After confirming hypertension, the patient should be categorized into one of three groups: pre-existing hypertension, pregnancy-induced hypertension (PIH), or pre-eclampsia. PIH, also known as gestational hypertension, occurs in 3-5% of pregnancies and is more common in older women. If a pregnant woman takes an ACE inhibitor or angiotensin II receptor blocker for pre-existing hypertension, it should be stopped immediately, and alternative antihypertensives should be started while awaiting specialist review.

Pregnancy-induced hypertension in association with proteinuria, which occurs in around 5% of pregnancies, may also cause oedema. The 2010 NICE guidelines recommend oral labetalol as the first-line treatment for hypertension during pregnancy. Oral nifedipine and hydralazine may also be used, depending on the patient’s medical history. It is important to manage hypertension during pregnancy effectively to reduce the risk of complications and ensure the health of both the mother and the baby.

The most appropriate management option for this patient is to offer the progestogen-only implant, as it can be safely inserted immediately after delivery and provides a long-term contraception option. Advising her that she doesn’t require contraception is not appropriate, as she is using a top-up formula and not exclusively breastfeeding. Offering the Mirena coil or restarting the combined oral contraceptive pill immediately are also not appropriate options, as they have specific timing requirements and potential risks for postpartum women.

After giving birth, women need to use contraception after 21 days. The Progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first 2 days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the Combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than 6 weeks postpartum. If breastfeeding is between 6 weeks to 6 months postpartum, it is UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk postpartum. After day 21, additional contraception should be used for the first 7 days.

The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after 4 weeks. Meanwhile, the Lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than 6 months postpartum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Epilepsy and Pregnancy: Considerations for Medication and Breastfeeding

Carbamazepine (CBZ) is present in breast milk, but only in small amounts. Breastfeeding mothers should be encouraged to continue breastfeeding as the levels of CBZ in breast milk are too low to cause any harm to the baby.

Prior to conception, it is recommended that women take folic acid at a dose of 5 mg daily to prevent neural tube defects in the fetus. However, it is not recommended for breastfeeding mothers.

For patients with well-controlled epilepsy, there is no increased risk of seizures during pregnancy or the postpartum period. While there is no routine need to monitor serum anti-epileptic concentrations, the NICE guidelines suggest monitoring levels in certain circumstances such as adjusting phenytoin dose, poor concordance, and suspected toxicity.

Overall, it is important for women with epilepsy to work closely with their healthcare provider to ensure the best possible outcomes for both mother and baby during pregnancy and breastfeeding.

Starting and Maintaining the Combined Oral Contraceptive Pill

The Combined Oral Contraceptive Pill (COC) can be started at any point during the menstrual cycle, as long as the woman is not pregnant. Once established on the COC, it is reasonable to give a 12-month prescription.

According to the latest guidance from the Faculty of Sexual and Reproductive Healthcare (FSRH), additional precautions are no longer required to maintain contraceptive efficacy when using antibiotics that are not enzyme inducers with the COCP for durations of 3 weeks or less. However, if the antibiotics or illness cause vomiting or diarrhea, the usual additional precautions relating to these conditions should be observed.

If seven COC pills have been taken, ovulation is suppressed for a further seven days, and emergency contraception is not required.

Starting Hormonal Contraception After Emergency Contraception

When starting hormonal contraception after taking progesterone-only emergency contraception, it is important to advise the use of additional contraception until contraceptive efficacy is established. If there is still a risk of pregnancy, the woman should express her preference for contraception immediately and be aware of the theoretical risk of fetal exposure to hormones, although evidence indicates no harm. A pregnancy test should be suggested at least three weeks after the last episode of unprotected sexual intercourse.

After taking progesterone-only emergency contraception, it is recommended to use condoms or avoid sex for seven days before starting most hormonal contraception. However, if ulipristal emergency contraception is taken, its effectiveness could be reduced if progestogen is taken in the following five days. Therefore, the quick start of suitable hormonal contraception should be delayed for five days (120 hours) after ulipristal.

Hormone Replacement Therapy (HRT) Options for Women

Women who have had a hysterectomy can use unopposed oestrogens, but those with a uterus must use regimens with both oestrogen and progestogen to avoid the risk of endometrial hyperplasia and potential malignant transformation. Postmenopausal women can use combined continuous regimens, while those still having periods can use cyclical HRT. Urogenital symptoms can be treated with topical oestrogens or non-hormonal vaginal moisturisers. Low dose combined pills may be an option for under 50s, but careful patient selection is necessary due to contraindications and cautions. It is important to discuss the risks and benefits of each option with a healthcare provider to determine the best course of treatment.

Infertility Management and Referral Criteria

Infertility is a common issue that affects many couples. According to the Clinical Knowledge Summaries, if a couple has been having regular unprotected sexual intercourse for one year and are without comorbidities that affect fertility, investigation into the cause of infertility should be initiated. If no cause is found, the couple should be referred for specialist input.

The referral criteria for infertility may vary between health authorities, so it is important to refer to local guidelines. However, in general, if the woman is younger than 36 years and history, examination, and investigations are normal in both partners, referral should be considered if the couple has not conceived after one year. If the woman is aged 36 years or older, referral should be considered after six months. Earlier referral may be necessary if there is a known cause for infertility, a history of factors that predispose to infertility, or if treatment is planned that may result in infertility.

It is important to ensure that the couple has been offered counselling before, during, and after investigation and treatment, regardless of the outcome. Infertility and its investigation and treatment can cause psychological stress, and infertility counsellors are provided by all licensed clinics in the UK through the British Infertility Counselling Association.

Atypical Endometrial Cells: Significance and Associated Risks

Diagnosis of atypical endometrial cells is of clinical significance as it may indicate the presence of significant uterine disease. In fact, more than one-third of women with histological follow-up have been found to have such conditions. Atypical endometrial cells may be associated with various conditions such as endometrial polyp, chronic endometritis, intrauterine contraceptive device (IUCD), endometrial hyperplasia, and endometrial carcinoma. The risk of carcinoma is particularly concerning, and patients should be referred to a gynaecologist for further investigation. Urgent referral is recommended, and patients should be seen within two weeks of referral to ensure timely diagnosis and treatment.

Key Points from the MBRRACE-UK Report for Primary Care

The MBRRACE-UK report is an important document that primary care practitioners should be familiar with. It is likely that AKT questions will be set on this report, so understanding the main take-home points is crucial. Here are some key points relating to epidemiology:

– There was a statistically non-significant increase in the overall maternal death rate in the UK between 2011-13 and 2014-16, indicating the need for implementation of the report’s recommendations to reduce maternal deaths.
– Maternal mortality rates are significantly higher among women from black and Asian ethnic backgrounds compared to white women, highlighting the need to address these disparities.
– Thrombosis and thromboembolism remain the leading cause of direct maternal death during or up to six weeks after the end of pregnancy.
– Maternal suicide is the third largest cause of direct maternal deaths, and eliciting any relevant history of mental health problems is essential for appropriate management of risk.
– Women with a high BMI should be given information about the symptoms of VTE, and those with a BMI ≥40 kg/m2 require postnatal thromboprophylaxis regardless of mode of delivery.
– Prescriptions for the entire postnatal course of low molecular weight heparin should be issued in secondary care to ensure women receive the full course without needing to visit their GP for another prescription.

By understanding these key points, primary care practitioners can provide better care for pregnant and postnatal women, and help reduce maternal mortality rates in the UK.

Parents are informed and the NHS website states that the daughter can still receive the vaccine even if the parents object.

The human papillomavirus (HPV) is a known carcinogen that infects the skin and mucous membranes. There are numerous strains of HPV, with strains 6 and 11 causing genital warts and strains 16 and 18 linked to various cancers, particularly cervical cancer. HPV infection is responsible for over 99.7% of cervical cancers, and testing for HPV is now a crucial part of cervical cancer screening. Other cancers linked to HPV include anal, vulval, vaginal, mouth, and throat cancers. While there are other risk factors for developing cervical cancer, such as smoking and contraceptive pill use, HPV vaccination is an effective preventative measure.

The UK introduced an HPV vaccine in 2008, initially using Cervarix, which protected against HPV 16 and 18 but not 6 and 11. This decision was criticized due to the significant disease burden caused by genital warts. In 2012, Gardasil replaced Cervarix as the vaccine used, protecting against HPV 6, 11, 16, and 18. Initially given only to girls, boys were also offered the vaccine from September 2019. The vaccine is offered to all 12- and 13-year-olds in school Year 8, with the option for girls to receive a second dose between 6-24 months after the first. Men who have sex with men under the age of 45 are also recommended to receive the vaccine to protect against anal, throat, and penile cancers.

Injection site reactions are common with HPV vaccines. It should be noted that parents may not be able to prevent their daughter from receiving the vaccine, as information given to parents and available on the NHS website makes it clear that the vaccine may be administered against parental wishes.

The guidelines indicate that there is no requirement to delay further, even if a caesarean section was performed.

Contraindications for Insertion of Intrauterine Contraceptive Devices

When it comes to the insertion of intrauterine contraceptive devices (IUDs), there are very few contraindications. However, it is important to note that some conditions may increase the risks associated with the procedure. According to the Faculty of Family Planning and Reproductive Health Care, there are certain conditions that fall under UKMEC Category 3, where the risks outweigh the benefits. These include insertion between 48 hours and 4 weeks postpartum, as well as initiation of the method in women with ovarian cancer.

On the other hand, UKMEC Category 4 lists conditions that pose an unacceptable risk for IUD insertion. These include pregnancy, current pelvic infection, puerperal sepsis, immediate post-septic abortion, unexplained vaginal bleeding, and uterine fibroids or anatomical abnormalities that distort the uterine cavity.

In addition, NICE guidelines from 2005 recommend screening for sexually transmitted infections (STIs) before IUD insertion. Women at risk of STIs should be tested for Chlamydia trachomatis and Neisseria gonorrhoeae, especially in areas where the latter is prevalent. Women who request it should also be tested for any STIs. For those at increased risk of STIs, prophylactic antibiotics should be given before IUD insertion if testing has not yet been completed.

It is important to consider these contraindications and guidelines before undergoing IUD insertion to ensure the safety and effectiveness of the procedure.

After giving birth, women need to use contraception after 21 days. The Progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first 2 days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the Combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than 6 weeks postpartum. If breastfeeding is between 6 weeks to 6 months postpartum, it is UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk postpartum. After day 21, additional contraception should be used for the first 7 days.

The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after 4 weeks. Meanwhile, the Lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than 6 months postpartum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

In the case of treating Chlamydia during pregnancy, erythromycin would be the most appropriate option among the listed antibiotics. Amoxicillin, azithromycin, or erythromycin can be used to treat Chlamydia during pregnancy. However, since the patient is allergic to penicillin, amoxicillin is not suitable. Doxycycline, which is the first-line treatment for uncomplicated Chlamydia in non-pregnant individuals, is not recommended during pregnancy due to its teratogenic effects. Co-amoxiclav is also not appropriate for treating Chlamydia and is contraindicated in this patient due to their penicillin allergy.

Chlamydia is the most common sexually transmitted infection in the UK caused by Chlamydia trachomatis. It is often asymptomatic but can cause cervicitis and dysuria in women and urethral discharge and dysuria in men. Complications include epididymitis, pelvic inflammatory disease, and infertility. Testing is done through nuclear acid amplification tests (NAATs) on urine or swab samples. Screening is recommended for sexually active individuals aged 15-24 years. Doxycycline is the first-line treatment, but azithromycin may be used if contraindicated. Partners should be notified and treated.

According to the guidelines of the Faculty of Sexual and Reproductive Health and the BNF, the recommended contraceptive method in this case is injectable progesterone. This method is not affected by drug interactions. However, as topiramate is an enzyme inducer, it can reduce the effectiveness of oestrogens and progesterone, which are components of combined contraceptive pills. Therefore, if a combined contraceptive pill is to be used, it should contain at least 50 micrograms of ethinyl estradiol. Barrier methods alone are not reliable and should not be used as the sole form of contraception. Progesterone-only pills and implants are not suitable due to the enhanced first pass metabolism of progesterone, which can result in decreased contraceptive efficacy.

Contraception for Women with Epilepsy

Women with epilepsy need to consider several factors when choosing a contraceptive method. The effectiveness of anti-epileptic medication can be affected by the contraceptive, and vice versa. Additionally, if a woman becomes pregnant while taking anti-epileptic medication, there is a risk of teratogenic effects on the fetus. To address these concerns, the Faculty of Sexual & Reproductive Healthcare (FSRH) recommends the consistent use of condoms in addition to other forms of contraception.

For women taking certain anti-epileptic medications such as phenytoin, carbamazepine, barbiturates, primidone, topiramate, and oxcarbazepine, the FSRH recommends using the combined oral contraceptive pill (COCP) or progestogen-only pill (POP) with a UK Medical Eligibility Criteria (UKMEC) rating of 3. The implant has a UKMEC rating of 2, while the Depo-Provera injection, intrauterine device (IUD), and intrauterine system (IUS) have a UKMEC rating of 1.

For women taking lamotrigine, the FSRH recommends using the COCP with a UKMEC rating of 3 or the POP, implant, Depo-Provera injection, IUD, or IUS with a UKMEC rating of 1. If a COCP is chosen, it should contain a minimum of 30 µg of ethinylestradiol.

In summary, women with epilepsy should carefully consider the potential interactions between their anti-epileptic medication and their chosen contraceptive method. Using condoms consistently in addition to other forms of contraception can help reduce the risk of unintended pregnancy and potential teratogenic effects on the fetus.

Following a miscarriage or abortion, the COC can be initiated without delay and provides immediate protection against pregnancy for women.

Women who are considering taking the combined oral contraceptive pill (COC) should receive counselling on various aspects. This includes the potential benefits and harms of the COC, such as its high effectiveness rate of over 99% when taken correctly, but also the small risk of blood clots, heart attacks, strokes, and increased risk of breast and cervical cancer. Additionally, advice on taking the pill should be provided, such as starting it within the first 5 days of the cycle to avoid the need for additional contraception, taking it at the same time every day, and considering tailored regimens that eliminate the pill-free interval. It is also important to discuss situations where efficacy may be reduced, such as vomiting or taking liver enzyme-inducing drugs. Finally, counselling should include information on STIs and the use of concurrent antibiotics, which may no longer require extra precautions except for enzyme-inducing antibiotics like rifampicin.

Overall, women should receive comprehensive counselling on the COC to make informed decisions about their reproductive health. This includes discussing the potential benefits and harms, advice on taking the pill, and situations where efficacy may be reduced. By providing this information, women can make informed decisions about their contraceptive options and reduce the risk of unintended pregnancies.

Anti-D Injection for Rhesus Antibody Sensitisation

Rhesus antibody sensitisation is a condition that requires careful consideration when deciding whether or not to administer anti-D injection. According to NICE guidelines, women should be given the option to discuss the need for this injection. If a woman has decided not to have any further children, immunisation with anti-D may not be necessary as long as she is sure her family is complete. However, it is important to note that patients often change their minds, and this needs to be discussed.

It is also important to consider the benefits and risks of anti-D injection. All preparations of anti-D carry a small risk of allergic reaction, as with the use of all medicines. The risk of D sensitisation is greatest during the first pregnancy and increased in ante-partum haemorrhage, third trimester miscarriage, termination, and with chorionic villus sampling. Therefore, it is crucial to weigh the potential benefits and risks of anti-D injection before making a decision.

Criteria for Determining Pregnancy Status in Starting Contraception

Health professionals can determine with reasonable certainty whether a woman is pregnant or not before starting contraception. This is important to ensure the safety and effectiveness of the chosen contraceptive method. According to CKS NICE, the following criteria can be used to determine pregnancy status:

– The woman has not had sexual intercourse since the last normal menses.
– The woman has used a reliable method of contraception correctly and consistently.
– The woman is within the first 7 days of the onset of a normal menstrual period.
– The woman is within 4 weeks postpartum for non-breastfeeding women.
– The woman is within the first 7 days post-termination of pregnancy or miscarriage.
– The woman is fully or nearly fully breastfeeding, amenorrhoeic, and less than 6 months postpartum.
– A pregnancy test is performed no sooner than 3 weeks since the last episode of unprotected sexual intercourse (UPSI) and is negative.

By following these criteria, health professionals can ensure that women are not inadvertently exposed to the risks of contraceptive methods during pregnancy. It is important to note that if there is any doubt about pregnancy status, a pregnancy test should be performed before starting contraception.

Statin therapy is not recommended during pregnancy due to the risk of congenital anomalies and potential impact on fetal development. Atorvastatin, in particular, is contraindicated during pregnancy and should be avoided three months prior to attempting pregnancy. However, lactulose and nasal steroids are considered safe for use during pregnancy. It is important for pregnant individuals with asthma to continue taking their medication to maintain good symptom control.

Statins are drugs that inhibit the action of HMG-CoA reductase, which is the enzyme responsible for cholesterol synthesis in the liver. However, they can cause adverse effects such as myopathy, liver impairment, and an increased risk of intracerebral hemorrhage in patients with a history of stroke. Statins should not be taken during pregnancy or in combination with macrolides. NICE recommends statins for patients with established cardiovascular disease, a 10-year cardiovascular risk of 10% or higher, type 2 diabetes mellitus, or type 1 diabetes mellitus with certain criteria. It is recommended to take statins at night, especially simvastatin, which has a shorter half-life than other statins. NICE recommends atorvastatin 20 mg for primary prevention and atorvastatin 80 mg for secondary prevention.

Mastitis is a common condition that affects breastfeeding women, typically occurring six weeks after giving birth. It can be difficult to distinguish between an engorged breast, blocked duct, non-infectious mastitis, and infected mastitis. Milk accumulation in breast tissue can cause an inflammatory response, leading to bacterial growth and resulting in a painful breast with fever, malaise, and a tender, red, swollen, and hard area of the breast.

If symptoms do not improve or worsen after 12-24 hours despite effective milk removal, or if a nipple fissure is infected, infectious mastitis should be suspected. Breast milk culture is not routinely required unless mastitis is severe, there has been no response to antibiotics, or this is recurrent mastitis.

Management of mastitis involves relieving pain with simple analgesia and warm compresses, and ensuring complete emptying of the breast after feeding. Breastfeeding should be continued as it improves milk removal and prevents nipple damage. If pain prevents breastfeeding, expressing breast milk by hand or pump is recommended until breastfeeding can be resumed.

Antibiotics are only recommended if necessary, and the first line antibiotic is flucloxacillin for 14 days (erythromycin if penicillin allergic). Intravenous antibiotics are rarely needed, but urgent referral to breast surgeons for drainage may be necessary if a breast abscess is suspected.

Breastfeeding Problems and Management

Breastfeeding can come with its own set of challenges, but most of them can be managed with proper care and attention. Some common issues include frequent feeding, nipple pain, blocked ducts, and nipple candidiasis. These problems can be addressed by seeking advice on positioning, breast massage, and using appropriate creams and suspensions.

Mastitis is a more serious condition that affects around 1 in 10 breastfeeding women. It is important to seek treatment if symptoms persist or worsen, including systemic illness, nipple fissures, or infection. The first-line antibiotic is flucloxacillin, and breastfeeding or expressing should continue during treatment. If left untreated, mastitis can lead to a breast abscess, which requires incision and drainage.

Breast engorgement is another common issue that can cause pain and discomfort. It usually occurs in the first few days after birth and can affect both breasts. Hand expression of milk can help relieve the discomfort of engorgement, and complications can be avoided by addressing the issue promptly.

Raynaud’s disease of the nipple is a less common but still significant problem that can cause pain and blanching of the nipple. Treatment options include minimizing exposure to cold, using heat packs, avoiding caffeine and smoking, and considering oral nifedipine.

Concerns about poor infant weight gain can also arise, prompting consideration of the above breastfeeding problems and an expert review of feeding. Monitoring of weight until weight gain is satisfactory is also recommended. With proper management and support, most breastfeeding problems can be overcome, allowing for a successful and rewarding breastfeeding experience.

Contraceptive Options for Postpartum Women

Postnatally, it is important for women to undergo a risk assessment for venous thromboembolism before considering their contraceptive options. Women with risk factors for venous thromboembolism within 6 weeks of childbirth, such as immobility, postpartum haemorrhage, and pre-eclampsia, should not use combined hormonal contraception. This applies to women who are breastfeeding and not breastfeeding, as the risk of venous thromboembolism is the same for both groups. However, the risk reduces quickly over the first three weeks postpartum, and the UKMEC advises that women who breastfeed should wait until six weeks postpartum before using combined hormonal contraception. Studies have shown that early initiation of combined hormonal contraception may have inconsistent effects on breastfeeding performance and conflicting data on infant outcomes, but overall, there is no negative impact on infant outcomes when initiated from six weeks postpartum.

Importance of Waiting for Cervical Epithelium Regeneration and Antimicrobial Treatment

It is crucial to wait for at least three months for the regeneration of the cervical epithelium after a screening test. This is because the epithelium needs time to heal and regenerate before another test is conducted. Rushing to re-sample before the regeneration of the epithelium can lead to inaccurate results, which can be detrimental to the patient’s health.

Moreover, if there is any suspicion of infection, antimicrobial treatment should be administered before re-sampling. This is because an infection can interfere with the accuracy of the test results, leading to false positives or false negatives. Therefore, it is essential to wait for the regeneration of the cervical epithelium and treat any suspected infection before conducting another screening test.

Contraception is still necessary after menopause. Women who are over 50 years old should use contraception for at least 12 months after their last period, while those under 50 years old should use it for at least 24 months after their last period.

Understanding Menopause and Contraception

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It typically occurs when a woman reaches the age of 51 in the UK. However, prior to menopause, women may experience a period known as the climacteric. During this time, ovarian function starts to decline, and women may experience symptoms such as hot flashes, mood swings, and vaginal dryness.

It is important for women to understand that they can still become pregnant during the climacteric period. Therefore, it is recommended to use effective contraception until a certain period of time has passed. Women over the age of 50 should use contraception for 12 months after their last period, while women under the age of 50 should use contraception for 24 months after their last period. By understanding menopause and the importance of contraception during the climacteric period, women can make informed decisions about their reproductive health.

Medical Management of Menorrhagia

Menorrhagia is a condition where menstrual loss exceeds 80 ml. While cyclic progestins have been used to treat menorrhagia, they have not been adequately tested in randomized controlled trials. On the other hand, tranexamic acid is considered the most effective medical intervention for menorrhagia.

According to NICE guidelines, if pharmaceutical treatment is appropriate for menorrhagia, hormonal or non-hormonal treatments should be considered in a specific order. The first option is the levonorgestrel-releasing intrauterine system, which provides long-term relief for at least 12 months. The second option is tranexamic acid, non-steroidal anti-inflammatory drugs (NSAIDs), or combined oral contraceptives. The third option is norethisterone (15 mg) daily from days 5 to 26 of the menstrual cycle or injected long-acting progestogens.

If hormonal treatments are not acceptable to the woman, then either tranexamic acid or NSAIDs can be used. It is important to note that a randomized trial of high-dose, longer-term cyclic norethisterone compared with a progestin-releasing IUD showed that flow was reduced by 87%. However, the current consensus of opinion favors tranexamic acid as the most effective medical intervention.

Women with a positive pregnancy test and abdominal, pelvic or cervical motion tenderness should be immediately referred for assessment to exclude ectopic pregnancy, which could be fatal. Referral should be made even if an ultrasound cannot be arranged immediately, as the patient may require monitoring in hospital. Serial hCG measurements should not be done in secondary care, and referral to a sexual health clinic alone is not appropriate.

Bleeding in the First Trimester: Causes and Management

Bleeding in the first trimester of pregnancy is a common concern for women, often leading them to seek medical attention. The main causes of bleeding during this time include miscarriage, ectopic pregnancy, implantation bleeding, cervical ectropion, vaginitis, trauma, and polyps. Of these causes, ectopic pregnancy is the most important to rule out as it can be life-threatening if missed.

To manage early bleeding, the National Institute for Health and Care Excellence (NICE) released guidelines in 2019. If a woman has a positive pregnancy test and experiences pain, abdominal or pelvic tenderness, or cervical motion tenderness, she should be referred immediately to an early pregnancy assessment service. If the pregnancy is over six weeks gestation or of uncertain gestation and the woman experiences bleeding, she should also be referred to an early pregnancy assessment service. A transvaginal ultrasound scan is the most important investigation to identify the location of the pregnancy and whether there is a fetal pole and heartbeat.

For pregnancies under six weeks gestation and no pain or risk factors for ectopic pregnancy, expectant management is appropriate. Women should be advised to return if bleeding continues or pain develops, to repeat a urine pregnancy test after 7-10 days and to return if it is positive. A negative pregnancy test indicates a miscarriage. By following these guidelines, healthcare providers can effectively manage bleeding in the first trimester and ensure the safety of both the mother and the developing fetus.

During pregnancy, fibroid degeneration can occur and may cause symptoms such as low-grade fever, pain, and vomiting. If an ultrasound scan shows no signs of inflammation in the appendix, it is unlikely that the patient has appendicitis. Given the presence of fibroids in the uterus, the patient is at risk of experiencing fibroid degeneration, particularly red degeneration, which can cause fever, pain, and vomiting. The absence of vaginal bleeding makes it unlikely that the patient is experiencing a threatened miscarriage. Ovarian torsion typically presents with pain and vomiting, but it is usually associated with risk factors such as ovarian cysts or enlargement.

Understanding Fibroid Degeneration

Uterine fibroids are non-cancerous growths that can develop in the uterus. They are known to be sensitive to oestrogen and can grow during pregnancy. However, if the growth of the fibroids exceeds their blood supply, they can undergo a type of degeneration known as red or ‘carneous’ degeneration. This condition is characterized by symptoms such as low-grade fever, pain, and vomiting.

Fortunately, fibroid degeneration can be managed conservatively with rest and analgesia. With proper care, the symptoms should resolve within 4-7 days. It is important to note that fibroid degeneration is a common occurrence and doesn’t necessarily indicate a serious underlying condition.

The BHIVA guidelines recommend that women on HAART with an undetectable viral load may consider vaginal delivery, but it is uncertain if this will be implemented in real-world situations. As for breastfeeding, the guidelines advise all HIV-positive mothers, regardless of their antiretroviral therapy and infant PEP, to exclusively use formula feeding from the time of birth.

HIV and Pregnancy: Guidelines for Minimizing Vertical Transmission

With the increasing prevalence of HIV infection among heterosexual individuals, there has been a rise in the number of HIV-positive women giving birth in the UK. In London, the incidence may be as high as 0.4% of pregnant women. The goal of treating HIV-positive women during pregnancy is to minimize harm to both the mother and fetus and to reduce the chance of vertical transmission.

To achieve this goal, various factors must be considered. Guidelines on this subject are regularly updated, and the most recent guidelines can be found using the links provided. Factors that can reduce vertical transmission from 25-30% to 2% include maternal antiretroviral therapy, mode of delivery (caesarean section), neonatal antiretroviral therapy, and infant feeding (bottle feeding).

To ensure that HIV-positive women receive appropriate care during pregnancy, NICE guidelines recommend offering HIV screening to all pregnant women. Additionally, all pregnant women should be offered antiretroviral therapy, regardless of whether they were taking it previously.

The mode of delivery is also an important consideration. Vaginal delivery is recommended if the viral load is less than 50 copies/ml at 36 weeks. Otherwise, a caesarean section is recommended, and a zidovudine infusion should be started four hours before beginning the procedure.

Neonatal antiretroviral therapy is also crucial in minimizing vertical transmission. Zidovudine is usually administered orally to the neonate if the maternal viral load is less than 50 copies/ml. Otherwise, triple ART should be used, and therapy should be continued for 4-6 weeks.

Finally, infant feeding is another important factor to consider. In the UK, all women should be advised not to breastfeed to minimize the risk of vertical transmission. By following these guidelines, healthcare providers can help minimize the risk of vertical transmission and ensure that HIV-positive women receive appropriate care during pregnancy.